Non-endogenous, constitutively activated known G protein-coupled receptors

ABSTRACT

The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is known (“known GPCRs”), and most particularly to mutated (non-endogenous) versions of the known GPCRs for use, most preferably in screening assays for the direct identification of candidate compounds as inverse agonists, agonists and partial agonists.

[0001] This patent application claims priority from U.S. Provisional Application No. 60/195,747, filed with the United States Patent and Trademark Office on Apr. 7, 2000; and is related to U.S. Ser. No. 09/170,496, filed with the United States Patent and Trademark Office on Oct. 13, 1998, each of which is incorporated in its entirety by reference.

FIELD OF THE INVENTION

[0002] The invention disclosed in this patent document relates to transmembrane receptors, and more particularly to G protein-coupled receptors for which the endogenous ligand has been identified (“known GPCR”), and specifically to known GPCRs that have been altered to establish or enhance constitutive activity of the receptor. Most preferably, the altered GPCRs are used for the direct identification of candidate compounds as receptor agonists, inverse agonists or partial agonists for use as therapeutic agents.

BACKGROUND OF THE INVENTION

[0003] Although a number of receptor classes exist in humans, by far the most abundant and therapeutically relevant is represented by the G protein-coupled receptor (GPCR or GPCRs) class. It is estimated that there are some 100,000 genes within the human genome, and of these, approximately 2%, or 2,000 genes, are estimated to code for GPCRs. Receptors, including GPCRs, for which the endogenous ligand has been identified are referred to as “known” receptors, while receptors for which the endogenous ligand has not been identified are referred to as “orphan” receptors. GPCRs represent an important area for the development of pharmaceutical products: from approximately 20 of the 100 known GPCRs, 60% of all prescription pharmaceuticals have been developed.

[0004] GPCRs share a common structural motif. (All these receptors have seven sequences of between 22 to 24 hydrophobic amino acids that form seven alpha helices, each of which spans the membrane (each span is identified by number, i.e., transmembrane-1 (TM-1), transmebrane-2 (TM-2), etc.). The transmembrane helices are joined by strands of amino acids between transmembrane-2 and transmembrane-3, transmembrane-4 and transmembrane-5, and transmembrane-6 and transmembrane-7 on the exterior, or “extracellular” side, of the cell membrane (these are referred to as “extracellular” regions 1, 2 and 3 (EC-1, EC-2 and EC-3), respectively). The transmembrane helices are also joined by strands of amino acids between transmembrane-1 and transmembrane-2, transmembrane-3 and transmembrane-4, and transmembrane-5 and transmembrane-6 on the interior, or “intracellular” side, of the cell membrane (these are referred to as “intracellular” regions 1, 2 and 3 (IC-1, IC-2 and IC-3), respectively). The “carboxy” (“C”) terminus of the receptor lies in the intracellular space within the cell, and the “amino” (“N”) terminus of the receptor lies in the extracellular space outside of the cell.

[0005] Generally, when an endogenous ligand binds with the receptor (often referred to as “activation” of the receptor), there is a change in the conformation of the intracellular region that allows for coupling between the intracellular region and an intracellular “G-protein.” It has been reported that GPCRs are “promiscuous” with respect to G proteins, i.e., that a GPCR can interact with more than one G protein. See, Kenakin, T., 43 Life Sciences 1095 (1988). Although other G proteins exist, currently, Gq, Gs, Gi, Gz and Go are G proteins that have been identified. Endogenous ligand-activated GPCR coupling with the G-protein begins a signaling cascade process (referred to as “signal transduction”). Under normal conditions, signal transduction ultimately results in cellular activation or cellular inhibition. It is thought that the IC-3 loop as well as the carboxy terminus of the receptor interact with the G protein.

[0006] Under physiological conditions, GPCRs exist in the cell membrane in equilibrium between two different conformations: an “inactive” state and an “active” state. A receptor in an inactive state is unable to link to the intracellular signaling transduction pathway to produce a biological response. Changing the receptor conformation to the active state allows linkage to the transduction pathway (via the G-protein) and produces a biological response.

[0007] A receptor may be stabilized in an active state by an endogenous ligand or a compound such as a drug. Recent discoveries, including but not exclusively limited to modifications to the amino acid sequence of the receptor, provide means other than endogenous ligands or drugs to promote and stabilize the receptor in the active state conformation. These means effectively stabilize the receptor in an active state by simulating the effect of an endogenous ligand binding to the receptor. Stabilization by such ligand-independent means is termed “constitutive receptor activation.”

[0008] Traditional ligand-dependent screens seek to indirectly identify compounds that antagonize the action of the ligand on the receptor in an effort to prevent ligand-induced activation of the receptor. However, such compounds, sometimes referred to as neutral-antagonists, generally would not be expected to affect the ligand-independent activity, or overactivity, of the receptor and the subsequent abnormal cellular response that can result from this overactivity. This is particularly relevant to a growing number of diseases, such as those identified in the table below, that have been linked to overactive GPCRs, because traditional neutral-antagonists will not block the abnormal ligand-independent activity of these receptors. Background Table 1 Disease Overactive GPCR Schizophrenia 5-HT2A, D2 Depression 5-HT2A Hyperthyroidism Thyrotropin Hypertension Angiotensin AT1A Asthma Adenosine A1 Melanoma MC-1 Retinitis Pigmentosa Rhodopsin receptor

SUMMARY OF THE INVENTION

[0009] Disclosed herein are non-endogenous versions of endogenous, known GPCRs and uses thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

[0010]FIG. 1 provides graphic results of comparative analysis of a co-transfection of non-endogenous TSHR-A6231 (“signal enhancer”) and an endogenous target receptor, in this case GPR24 (“GPR24 wt”), versus non-endogenous, constitutively activated versions of the target receptor GPR24 (“T255K,” “T255K/T257R,” “24-IC3-SST2,” “C305Y,” “P271L,” “W269C,” “W269F,” “W269L,” “F265I,” I261Q,” and “D140N”) co-transfected with non-endogenous TSHR-A623I, utilizing an adenylyl cyclase assay. This assay involved the addition of TSH and MCH, the endogenous ligands for TSHR and GPR24, respectively.

[0011]FIG. 2 provides graphic results of comparative analysis of a co-transfection of non-endogenous signal enhancer TSBR-A623I (with and without TSH) and endogenous target receptor GPR5 (“GPR5 wt”), versus non-endogenous, constitutively activated target receptor GPR5 (“V224K”) co-transfected with non-endogenous TSHR-A623I (with and without TSH), utilizing an adenylyl cyclase assay.

[0012] FIGS. 3A-3E provide a diagrammatic representation of the signal measured comparing CMV, non-endogenous, constitutively activated GPCRs, utilizing 8XCRE-Luc reporter plasmid.

[0013]FIG. 4 provides an illustration of IP₃ production from several non-endogenous versions of GPR24 as compared with the endogenous version of this receptor.

[0014]FIG. 5 is a graphic representation of the results of a membrane-based cyclic AMP assay providing comparative results for constitutive signaling of TSHR-A623K:Fusion Protein and a control vector (pCMV).

DETAILED DESCRIPTION

[0015] The scientific literature that has evolved around receptors has adopted a number of terms to refer to ligands having various effects on receptors. For clarity and consistency, the following definitions will be used throughout this patent document. To the extent that these definitions conflict with other definitions for these terms, the following definitions shall control:

[0016] AGONISTS shall mean materials (e.g., ligands, candidate compounds) that activate the intracellular response when they bind to the receptor, or enhance GTP binding to membranes.

[0017] AMINO ACID ABBREVIATIONS used herein are set out in Table A: TABLE A ALANINE ALA A ARGININE ARG R ASPARAGINE ASN N ASPARTIC ACID ASP D CYSTEINE CYS C GLUTAMIC ACID GLU E GLUTAMINE GLN Q GLYCINE GLY G HISTIDINE HIS H ISOLEUCINE ILE I LEUCINE LEU L LYSINE LYS K METHIONINE MET M PHENYLALANINE PHE F PROLINE PRO P SERINE SER S THREONINE THR T TRYPTOPHAN TRP W TYROSINE TYR Y VALINE VAL V

[0018] PARTIAL AGONISTS shall mean materials (e.g., ligands, candidate compounds) that activate the intracellular response when they bind to the receptor to a lesser degree/extent than do agonists, or enhance GTP binding to membranes to a lesser degree/extent than do agonists.

[0019] ANTAGONIST shall mean materials (e.g., ligands, candidate compounds) that competitively bind to the receptor at the same site as the agonists but which do not activate the intracellular response initiated by the active form of the receptor, and can thereby inhibit the intracellular responses by agonists or partial agonists. ANTAGONISTS do not diminish the baseline intracellular response in the absence of an agonist or partial agonist.

[0020] CANDIDATE COMPOUND, in the context of the disclosed invention, shall mean a small molecule (for example, and not limitation, a chemical compound) that is amenable to a screening technique.

[0021] COMPOSITION means a material comprising at least one component; a “pharmaceutical composition” is an example of a composition.

[0022] COMPOUND EFFICACY shall mean a measurement of the ability of a compound to inhibit or stimulate receptor functionality, as opposed to receptor binding affinity. Exemplary means of detecting compound efficacy are disclosed in the Example section of this patent document.

[0023] CODON shall mean a grouping of three nucleotides (or equivalents to nucleotides) which generally comprise a nucleoside (adenosine (A), guanosine (G), cytidine (C), uridine (U) and thymidine (T)) coupled to a phosphate group and which, when translated, encodes an amino acid.

[0024] CONSTITUTIVELY ACTIVATED RECEPTOR shall mean a receptor subject to constitutive receptor activation. A constitutively activated receptor can be endogenous or non-endogenous.

[0025] CONSTITUTIVE RECEPTOR ACTIVATION shall mean stabilization of a receptor in the active state by means other than binding of the receptor with its endogenous ligand or a chemical equivalent thereof.

[0026] CONTACT or CONTACTING shall mean bringing at least two moieties together, whether in an in vitro system or an in vivo system.

[0027] DIRECTLY IDENTIFYING or DIRECTLY IDENTIFIED, in relationship to the phrase “candidate compound”, shall mean the screening of an candidate compound against a constitutively activated receptor, preferably a constitutively activated receptor, and most preferably against a constitutively activated G protein-coupled cell surface receptor, and assessing the compound efficacy of such compound. This phrase is, under no circumstances, to be interpreted or understood to be encompassed by or to encompass the phrase “indirectly identifying” or “indirectly identified.”

[0028] ENDOGENOUS shall mean a material that a mammal naturally produces. ENDOGENOUS in reference to, for example and not limitation, the term “receptor,” shall mean that which is naturally produced by a mammal (for example, and not limitation, a human) or a virus. By contrast, the term NON-ENDOGENOUS in this context shall mean that which is not naturally produced by a mammal (for example, and not limitation, a human) or a virus. For example, and not limitation, a receptor which is not constitutively active in its endogenous form, but when manipulated becomes constitutively active, is most preferably referred to herein as a “non-endogenous, constitutively activated receptor.” Both terms can be utilized to describe both “in vivo” and “in vitro” systems. For example, and not limitation, in a screening approach, the endogenous or non-endogenous receptor may be in reference to an in vitro screening system. As a further example and not limitation, where the genome of a mammal has been manipulated to include a non-endogenous constitutively activated receptor, screening of a candidate compound by means of an in vivo system is viable.

[0029] G PROTEIN COUPLED RECEPTOR FUSION PROTEIN and GPCR FUSION PROTEIN, in the context of the invention disclosed herein, each mean a non-endogenous protein comprising an endogenous, constitutively activate GPCR or a non-endogenous, constitutively activated GPCR fused to at least one G protein, most preferably the alpha (α) subunit of such G protein (this being the subunit that binds GTP), with the G protein preferably being of the same type as the G protein that naturally couples with endogenous GPCR. For example, and not limitation, in an endogenous state, if the G protein “Gsα” is the predominate G protein that couples with the GPCR, a GPCR Fusion Protein based upon the specific GPCR would be a non-endogenous protein comprising the GPCR fused to Gsα; in some circumstances, as will be set forth below, a non-predominant G protein can be fused to the GPCR. The G protein can be fused directly to the c-terminus of the constitutively active GPCR or there may be spacers between the two.

[0030] HOST CELL shall mean a cell capable of having a Plasmid and/or Vector incorporated therein. In the case of a prokaryotic Host Cell, a Plasmid is typically replicated as a autonomous molecule as the Host Cell replicates (generally, the Plasmid is thereafter isolated for introduction into a eukaryotic Host Cell); in the case of a eukaryotic Host Cell, a Plasmid is integrated into the cellular DNA of the Host Cell such that when the eukaryotic Host Cell replicates, the Plasmid replicates. Preferably, for the purposes of the invention disclosed herein, the Host Cell is eukaryotic, more preferably, mammalian, and most preferably selected from the group consisting of Hek-293, Hek-293T and COS-7 cells.

[0031] INDIRECTLY IDENTIFYING or INDIRECTLY IDENTIFIED means the traditional approach to the drug discovery process involving identification of an endogenous ligand specific for an endogenous receptor, screening of candidate compounds against the receptor for determination of those which interfere and/or compete with the ligand-receptor interaction, and assessing the efficacy of the compound for affecting at least one second messenger pathway associated with the activated receptor.

[0032] INHIBIT or INHIBITING, in relationship to the term “response” shall mean that a response is decreased or prevented in the presence of a compound as opposed to in the absence of the compound.

[0033] INVERSE AGONISTS shall mean materials (e.g., ligand, candidate compounds) which bind to either the endogenous form of the receptor or to the constitutively activated form of the receptor, and which inhibit the baseline intracellular response initiated by the active form of the receptor below the normal base level of activity which is observed in the absence of agonists or partial agonists, or decrease GTP binding to membranes. Preferably, the baseline intracellular response is inhibited in the presence of the inverse agonist by at least 30%, more preferably by at least 50%, and most preferably by at least 75%, as compared with the baseline response in the absence of the inverse agonist.

[0034] KNOWN RECEPTOR shall mean an endogenous receptor for which the endogenous ligand specific for that receptor has been identified.

[0035] LIGAND shall mean an endogenous, naturally occurring molecule specific for an endogenous, naturally occurring receptor.

[0036] MUTANT or MUTATION in reference to an endogenous receptor's nucleic acid and/or amino acid sequence shall mean a specified change or changes to such endogenous sequences such that a mutated form of an endogenous, non-constitutively activated receptor evidences constitutive activation of the receptor. In terms of equivalents to specific sequences, a subsequent mutated form of a human receptor is considered to be equivalent to a first mutation of the human receptor if (a) the level of constitutive activation of the subsequent mutated form of a human receptor is substantially the same as that evidenced by the first mutation of the receptor; and (b) the percent sequence (amino acid and/or nucleic acid) homology between the subsequent mutated form of the receptor and the first mutation of the receptor is at least about 80%, more preferably at least about 90% and most preferably at least 95%. Ideally, and owing to the fact that the most preferred cassettes disclosed herein for achieving constitutive activation includes a single amino acid and/or codon change between the endogenous and the non-endogenous forms of the GPCR, the percent sequence homology should be at least 98%.

[0037] NON-ORPHAN RECEPTOR shall mean an endogenous naturally occurring molecule specific for an endogenous naturally occurring ligand wherein the binding of a ligand to a receptor activates an intracellular signaling pathway.

[0038] ORPHAN RECEPTOR shall mean an endogenous receptor for which the endogenous ligand specific for that receptor has not been identified or is not known.

[0039] PHARMACEUTICAL COMPOSITION shall mean a composition comprising at least one active ingredient, whereby the composition is amenable to investigation for a specified, efficacious outcome in a mammal (for example, and not limitation, a human). Those of ordinary skill in the art will understand and appreciate the techniques appropriate for determining whether an active ingredient has a desired efficacious outcome based upon the needs of the artisan.

[0040] PLASMID shall mean the combination of a Vector and cDNA. Generally, a Plasmid is introduced into a Host Cell for the purposes of replication and/or expression of the cDNA as a protein.

[0041] STIMULATE or STIMULATING, in relationship to the term “response” shall mean that a response is increased in the presence of a compound as opposed to in the absence of the compound.

[0042] VECTOR in reference to cDNA shall mean a circular DNA capable of incorporating at least one cDNA and capable of incorporation into a Host Cell.

[0043] The order of the following sections is set forth for presentational efficiency and is not intended, nor should be construed, as a limitation on the disclosure or the claims to follow.

[0044] A. Introduction

[0045] Constitutively active forms of known G protein-coupled receptors, disclosed in the present patent document, can be obtained by site-directed mutational methods, well-known to those skilled in the art. A constitutively active receptor useful for direct identification of candidate compounds is preferably achieved by mutating the receptor at a specific location within an intracellular loop, most preferably within the intracellular loop three (IC3) region. Such mutation can produce a non-endogenous receptor that is intended to be constitutively activated, as evidenced by an increase in the functional activity of the receptor, for example, an increase in the level of second messenger activity. While standard methods of site-directed mutagenesis may be employed, a preferred method is one that is disclosed in a co-pending, commonly assigned patent document U.S. application Ser. No. 09/170,496, incorporated herein by reference.

[0046] Table B below lists known endogenous GPCRs that have been converted to non-endogenous versions thereof, their respective G protein and endogenous ligand. TABLE B Known GPCRs G Protein Endogenous Ligand 5HT-1A Gi Serotonin 5HT-1B Gi Serotonin 5HT-1D Gi Serotonin 5HT-1E Gi Serotonin 5HT-1F Gi Serotonin 5HT-2B Gi Serotonin 5HT-4A N/I Serotonin 5HT-4B N/I Serotonin 5HT-4C N/I Serotonin 5HT-4D N/I Serotonin 5HT-4E N/I Serotonin 5HT-5A Unknown Serotonin 5HT-6 Gs Serotonin 5HT-7 Gs Serotonin AVPR1A Gq Arginine Vasopressin AVPRIB Gq Arginine Vasopressin AVPR2 Gs Arginine Vasopressin BBR3 Gq Bombesin BDKR1 Gq Bradykinin BDKR2 Gq Bradykinin C3a N/I Anaphylatoxin C5a N/I Anaphylatoxin CB1 Gi Cannabinoid CB2 Gi Cannabinoid CCR2b Gi Monocyte chemoattractant (MCP) CCR3 Gi Eotaxin, Leukotactin-1, RANTES, MCP CCR5 Gi MIP-1α, MIP-1β, RANTES CCR8 Gi I-309, TARC, MIP-1β CCR9 N/I Thymus-expressed chemokine (TECK) CRFR1 Gs Corticotropin-releasing- factor CXCR4 Gi SDF1 Dopamine D1 Gs Dopamine Dopamine D2 Gi Dopamine Dopamine D3 Gi Dopamine Dopamine D5 Gs Dopamine ETA Gq Endothelin ETB Gq Endothelin FPR1 N/I Formylpeptide FPRL1 N/I formylpeptide GALR1 Gi Galanin GALR2 Gi/Gq Galanin GIP N/I Gastric inhibitory polypeptide mGluR1 Gq Glutamate GPR5 N/I Single C motif-1 (SMC-1) GPR24 Gi/Gq Melanin Concentrating (also known as Hormone MCH or SLC-1) GRPR Gq Gastrin releasing peptide M1 Gq Acetylcholine M2 Gi Acetylcholine M3 Gq Acetylcholine M4 Gi Acetylcholine M5 Gq Acetylcholine MC3 Gs Melanocortin NK1R Gq Substance P NK2R Gq Neurokinin-A NK3R Gq Neurokinin-B NMBR Gq Neuromedin B NPY5 Gi Neuropeptide Y NTSR1 Gq Neurotensin NTSR2 Gq Neurotensin OPRD Gi Opiod OPRL1 Gi Opiod OPRK Gi Opiod OPRM Gi Opiod OPRM1A Gi Opiod OX₁R N/I Orexin OX₂R N/I Orexin PACAP Gs Pituitary adenylyl cyclase activating peptide PAF N/I Platelet activating factor PGE EP1 N/I Prostaglandin PGE EP2 Gs Prostaglandin PGE EP4 N/I Prostaglandin PTHR1 N/I Parathyroid hormone PTHR2 N/I Parathyroid hormone SCTR Gs Secretin SST1 Gi Somatostatin SST2 Gi Somatostatin SST3 Gi Somatostatin SST4 Gi Somatostatin SST5 Gi Somatostatin TSHR Gs Thyroid Stimulating Hormone VIPR Gs Vasoactive Intestinal Peptide VIPR2 Gs Vasoactive Intestinal Peptide

[0047] B. Receptor Screening

[0048] Screening candidate compounds against a non-endogenous, constitutively activated version of the known GPCRs disclosed herein allows for the direct identification of candidate compounds which act at the cell surface of the receptor, without requiring use of the receptor's endogenous ligand. By determining areas within the body where the endogenous version of known GPCRs disclosed herein is expressed and/or over-expressed, it is possible to determine related disease/disorder states which are associated with the expression and/or over-expression of the receptor; such an approach is disclosed in this patent document.

[0049] Table C below lists the known GPCRs and tissues within the body are expressed and/or over-expressed. The listed references provide support for such tissue expression. TABLE C Known GPCRs Location of Expression Reference 5HT-1A N/I N/I 5HT-1B Striatum Jin, H. et al., 267(9) J Biol Chem 5735 (1992) 5HT-1D Cerebral cortex Weinshank, R. L. et al., 89(8) Proc Natl Acad Sci USA 3630 (1992) 5HT-1E N/I N/I 5HT-1F Brain Adham, N. et al., 90 Proc Natl Acad Sci USA 408 (1993) 5HT-2B Various tissues, including Kursar, J. D., 46(2_Mol Brain Pharmacol 227 (1994) 5HT-4A Brain, Intestine and Atrium Blondel, O. et al., 70 J Nerochem 2252 (1998) 5HT-4B Brain, Intestine and Atrium Blondel, O. et al., 70 J Nerochem 2252 (1998) 5HT-4C Brain, Intestine and Atrium Blondel, O. et al., 70 J Nerochem 2252 (1998) 5HT-4D Intestine Blondel, O. et al., 70 J Neurochem 2252 (1998) 5HT-4E Brain Claeysen, S. et al., 55(5) Mol Pharmacol 910 (1999) 5HT-5A Brain Rees, S. et al., 355(3) FEBS Lett 242 (1994) 5HT-6 Caudate Nucleus Kohen, R. et al., 66(1) J Neurochem 47 (1996) 5HT-7 Brain, Coronary artery Bard, J. A. et al., 268(31) J Biol Chem 23422 (1993) AVPR1A N/I N/I AVPR1B Pituitary Sugimoto, T. et al., 269(43) J. Biol. Chem 27088 (1994) AVPR2 Lung, Kidney Fay, M. J., et al., 17(3) Peptides 477 (1996) BBR3 Testis, Lung carcinoma Fathi, Z. et al., 268(8) J. Biol. Chem. 5979 (1993) BDKR1 N/I N/I BDKR2 N/I N/I C3a Lung, Spleen, Ovary, Ames, R. et al., 271(34) J. Placenta, Small Intestine and Biol. Chem 20231(1996) Brain C5a N/I N/I CB1 Brain Gerard, C. M. et al., 279 Biochem J. 129 (1991) CB2 Spleen, Macrophage Munro, S. et al., 365(6441) Nature 61 (1993) CCR2b N/I N/I CCR3 Endometrium Zhang, J. et al., 62(2) Biol Reprod 404 (2000) CCR5 Thymus, Spleen Raport, C. J. et al., 271(29) J Biol Chem 17161 (1996) CCR8 Thymus, Spleen and Lymph Napolitano M. et al., Forum nodes (Geneva) 1999 Oct- Dec;9(4):315-24 CCR9 Thymus Zaballos, A. et al., 162(10) J. Immunol 5671 (1999) CRFR1 Brain, Pituitary Perrin, M. H. et al., 133(6) Endocrinology 3058 (1993) CXCR4 Colonic epithelial cells Jordan, N. J. et al., 104(8) J Clin Invest 1061 (1999) Dopamine Caudate, Nucleus accumbens Dearry, A. et al., 347 Nature D1 and Olfactory tubercle 72 (1990) Dopamine Retina Dearry, A. et al., 11(5) Cell D2 Mol. Neurobiol. 437 (1991) Dopamine Brain Schmauss, C. et al., 90(19) D3 Proc Natl Acad Sci USA 8942 (1993) Dopamine Brain Sunahara, R. K. et al., D5 350(6319) Nature 614 (1991) ETA Placenta, Uterus, Testis, Adachi, M. et al., 180(3) Adrenal gland Biochem Biophys Res Commun 1265 (1991) ETB N/I N/I FPR1 N/I N/I FPRL1 N/I N/I GALR1 Hypothalamic Gundlach, A. L. et al., 863 paraventricular, Supraoptic Ann NY Acad Sci 241 nuclei (1998) GALR2 Hypothalamus, Fathi, Z. et al., 51 Brain Res Hippocampus, Anterior Mol Brain Res 49 (1997) pituitary GIP N/I N/I mGluR1 Brain Stephan, D. et al., 35(12) Neuropharmacology 1649 (1996) GPR5 Leukocyte cells Shan, L. et al., 268(3) Biochem Biophys Res Commun 938 (2000) GPR24 Fore-brain, Hypothalamus Kolakowki L F Jr. et al., (also knowm as MCH or SLC-1) 398(2-3) FEBS Lett 253 (1996) GRPR Lung carcinoma cells Corjay, M. H. et al., 266 Jo BiolChem 18771 (1991) M1 Heart, Pancreas and Neuronal Peralta, E. G. et al., Embo J. cell lines 6(13) 3923 (1987) M2 Heart, Pancreas and Neuronal Peralta, E. G. et al., Embo J. cell lines 6(13) 3923 (1987) M3 Heart, Pancreas and Neuronal Peralta, E. G. et al., Embo J. cell lines 6(13) 3923 (1987) M4 Heart, Pancreas and Neuronal Peralta, E. G. et al., Embo J. cell lines 6(13) 3923 (1987) M5 Brain Bonner, T. I. et al., Neuron 1(5), 403 (1988) MC3 Brain, Placenta, Gut Gantz I. et al., 268(11) Jo Biol Chem 8246 (1993) NK1R Spinal cord, Lung Taked, Y. et aL, 179(3) Biochem Biophys Res Commun 1232(1991) NK2R N/I N/I NK3R N/I N/I NMBR Lung carcinoma cells Corjay, M. H. et al., 266 Jo Biol Chem 18771 (1991) NPY5 Hypothalamus Gerald, C. et al., 382 Nature 168 (1996) NTSR1 Brain, Small intestine Vita, N. et al., 17 (1-2) FEBS Lett 139 (1993) NTSR2 N/I N/I OPRD Peripheral blood Wick, M. J. et al., 64(1) J. lymphocytes Neuroimmunol 29 (1996) OPRL1 N/I N/I OPRK Placenta, Brain Manson, E. et al., 202(3) Biochem Biophys Res Commun 1431 (1994) OPRM N/I N/I OPRM1A N/I N/I OX₁R Hypothalamus Sakurai T. et al., 92 Cell 573 (1998) OX₂R Hypothalamus Sakural T. et al., 92 Cell 573 (1998) PACAP Brain Ogi, K. et al., 196(3) Biochem Biophys Res Commun 1511 (1993) PAF N/I N/I PGE EP1 Kidney Watabe, A. et al., 268(27) J Biol Chem 20175 (1993) PGE EP2 Small Intestine Bastien, L. et al., 269(16) J. Biol. Chem 11873 (1994) PGE EP4 N/I N/I PTHR1 Bone, Kidney Schipani, E. et al., 132(5) Endocrinology 2157 (1993) PTHR2 Brain, Pancreas Usdin, T. B. et al., 270(26) J. Biol Chem 15455 (1995) SCTR Pancreas, Intestine Chow, B. K., 212(1) Biochem Biophys Res Commun 204 (1995) SST1 Jejunum, Stomach Yamada Y. et al., 89 Proc Natl Acad Sci USA 251 (1992) SST2 Cerebrum, Kidney Yamada Y. et al., 89 Proc Natl Acad Sci USA 251 (1992) SST3 Brain, Pancreatic islet Yamada Y. et al., 6 Mol Endocrinol 2136 (1992) SST4 Fetal, Adult Brain, Lung Rohser L. et al., 90(9) Pro Natl Acad Sci USA 4146 (1993) SST5 Pituitary Panetta R. et al., 45(3) mol Pharmacol 417 (1994) TSHR Retro-orbital tissues, Feliciello A. et al 342 Lancet Exophthalmos 337 (1993) VIPR Lung Sreedharan, S. P. et al., 193(2) Biochem Biophys Res Commun 546 (1993) VIPR2 Skeletal muscle Adamou, J. E. et al., 209(2) Biochem Biophys Res Commun 385 (1995)

[0050] Creation of a non-endogenous version of a known GPCR that may evidence constitutive activity is most preferably based upon the distance from a proline residue located within TM6 of the GPCR; this technique is disclosed in co-pending and commonly assigned patent document U.S. Ser. No. 09/170,496, incorporated herein by reference. This technique is not predicated upon traditional sequence “alignment” but rather a specified distance from the aforementioned TM6 proline residue. By mutating the amino acid residue located 16 amino acid residues from this residue (presumably located in the IC3 region of the receptor) to, most preferably, a lysine residue, such activation may be obtained. Other amino acid residues may be used for the mutation, but lysine is most preferred.

[0051] D. Disease/Disorder Identification and/or Selection

[0052] As will be set forth in greater detail below, most preferably inverse agonists, partial agonists and agonists in the form of small molecule chemical compounds to the non-endogenous, constitutively activated GPCR can be identified by the methodologies of this invention. Such compounds are ideal candidates as lead modulators in drug discovery programs for treating diseases or disorders associated with a particular receptor. The ability to directly identify such compounds to the GPCR, in the absence of use of the receptor's endogenous ligand, allows for the development of pharmaceutical compositions.

[0053] Preferably, in situations where it is unclear what disease or disorder may be associated with a receptor; the DNA sequence of the known GPCR is used to make a probe for (a) dot-blot analysis against tissue-mRNA, and/or (b) RT-PCR identification of the expression of the receptor in tissue samples. The presence of a receptor in a tissue source, or a diseased tissue, or the presence of the receptor at elevated concentrations in diseased tissue compared to a normal tissue, can be preferably utilized to identify a correlation with a treatment regimen, including but not limited to, a disease associated with that disease. Receptors can equally well be localized to regions of organs by this technique. Based on the known functions of the specific tissues to which the receptor is localized, the putative functional role of the receptor can be deduced.

[0054] E. Screening of Candidate Compounds

[0055] 1. Generic GPCR Screening Assay Techniques

[0056] When a G protein receptor becomes constitutively active, it binds to a G protein (e.g., Gq, Gs, Gi, Gz, Go) and stimulates the binding of GTP to the G protein. The G protein then acts as a GTPase and slowly hydrolyzes the GTP to GDP, whereby the receptor, under normal conditions, becomes deactivated. However, constitutively activated receptors continue to exchange GDP to GTP. A non-hydrolyzable analog of GTP, [³⁵S]GTPγS, can be used to monitor enhanced binding to membranes which express constitutively activated receptors. It is reported that [³⁵S]GTPγS can be used to monitor G protein coupling to membranes in the absence and presence of ligand. An example of this monitoring, among other examples well-known and available to those in the art, was reported by Traynor and Nahorski in 1995. The preferred use of this assay system is for initial screening of candidate compounds because the system is generically applicable to all G protein-coupled receptors regardless of the particular G protein that interacts with the intracellular domain of the receptor.

[0057] 2. Specific GPCR Screening Assay Techniques

[0058] Once candidate compounds are identified using the “generic” G protein-coupled receptor assay (i.e., an assay to select compounds that are agonists, partial agonists, or inverse agonists), further screening to confirm that the compounds have interacted at the receptor site is preferred. For example, a compound identified by the “generic” assay may not bind to the receptor, but may instead merely “uncouple” the G protein from the intracellular domain.

[0059] a. Gs, Gz and Gi.

[0060] Gs stimulates the enzyme adenylyl cyclase. Gi (and Gz and Go), on the other hand, inhibit this enzyme. Adenylyl cyclase catalyzes the conversion of ATP to cAMP; thus, constitutively activated GPCRs that couple the Gs protein are associated with increased cellular levels of cAMP. On the other hand, constitutively activated GPCRs that couple Gi (or Gz, Go) protein are associated with decreased cellular levels of cAMP. See, generally, “Indirect Mechanisms of Synaptic Transmission,” Chpt. 8, From Neuron To Brain (3^(rd) Ed.) Nichols, J. G. et al eds. Sinauer Associates, Inc. (1992). Thus, assays that detect cAMP can be utilized to determine if a candidate compound is, e.g., an inverse agonist to the receptor (i.e., such a compound would decrease the levels of cAMP). A variety of approaches known in the art for measuring cAMP can be utilized; a most preferred approach relies upon the use of anti-cAMP antibodies in an ELISA-based format. Another type of assay that can be utilized is a second messenger reporter system assay. Promoters on genes drive the expression of the proteins that a particular gene encodes. Cyclic AMP drives gene expression by promoting the binding of a cAMP-responsive DNA binding protein or transcription factor (CREB) that then binds to the promoter at specific sites called cAMP response elements and drives the expression of the gene. Reporter systems can be constructed which have a promoter containing multiple cAMP response elements before the reporter gene, e.g., β-galactosidase or luciferase. Thus, a constitutively activated Gs-linked receptor causes the accumulation of cAMP that then activates the gene and expression of the reporter protein. The reporter protein such as β-galactosidase or luciferase can then be detected using standard biochemical assays (Chen et al. 1995).

[0061] b. Go and Gq.

[0062] Gq and Go are associated with activation of the enzyme phospholipase C, which in turn hydrolyzes the phospholipid PIP₂, releasing two intracellular messengers: diacycloglycerol (DAG) and inistol 1,4,5-triphoisphate (IP₃). Increased accumulation of PP₃ is associated with activation of Gq- and Go-associated receptors. See, generally, “Indirect Mechanisms of Synaptic Transmission,” Chpt. 8, From Neuron To Brain (3^(rd) Ed.) Nichols, J. G. et al eds. Sinauer Associates, Inc. (1992). Assays that detect IP₃ accumulation can be utilized to determine if an candidate compound is, e.g., an inverse agonist to a Gq- or Go-associated receptor (i.e., such a compound would decrease the levels of IP₃). Gq-associated receptors can also be examined using an AP1 reporter assay in that Gq-dependent phospholipase C causes activation of genes containing AP1 elements; thus, activated Gq-associated receptors will evidence an increase in the expression of such genes, whereby inverse agonists thereto will evidence a decrease in such expression, and agonists will evidence an increase in such expression. Commercially available assays for such detection are available.

[0063] 3. Ligand-Based Confirmation Assays

[0064] The candidate compounds directly identified using the techniques (or equivalent techniques) above are then, most preferably, verified using a ligand-based verification assay, such as the one set forth in the protocol of Example 8. The importance here is that the candidate compound be directly identified; subsequent confirmation, if any, using the endogenous ligand, is merely to confirm that the directly identified candidate compound has targeted the receptor.

[0065] For example, sumatriptan is a well-known agonist of the 5-HT1B and 5-HT1D receptors, while naltrindole is a well-known antagonist to the OPMID receptor. Accordingly, an agonist (sumatriptan) and/or antagonist (naltrindole) competitive binding assay(s) can be used to confirm that those candidate compounds directly identified using a ligand independent screening technique comprising non-endogenous, constitutively activated 5-HT1B or 5-HT1D, and non-endogenous constitutively activated OPM1D, respectfully, may be used for confirmatory purposes. Those skilled in the art are credited with the ability to select techniques for ligand-based confirmation assays.

[0066] 4. GPCR Fusion Protein

[0067] The use of a non-endogenous, constitutively activated GPCR, for use in screening of candidate compounds for the direct identification of inverse agonists, agonists and partial agonists, provides an interesting screening challenge in that, by definition, the receptor is active even in the absence of an endogenous ligand bound thereto. Thus, in order to differentiate between, e.g., the non-endogenous receptor in the presence of a candidate compound and the non-endogenous receptor in the absence of that compound, with an aim of such a differentiation to allow for an understanding as to whether such compound may be an inverse agonist, agonist, partial agonist or has no affect on such a receptor, it is preferred that an approach be utilized that can enhance such differentiation. A preferred approach is the use of a GPCR Fusion Protein.

[0068] Generally, once it is determined that a non-endogenous GPCR has been constitutively activated using the assay techniques set forth above (as well as others), it is possible to determine the predominant G protein that couples with the endogenous GPCR. Coupling of the G protein to the GPCR provides a signaling pathway that can be assessed. Because it is most preferred that screening take place by use of a mammalian expression system, such a system will be expected to have endogenous G protein therein. Thus, by definition, in such a system, the non-endogenous, constitutively activated GPCR will continuously signal. In this regard, it is preferred that this signal be enhanced such that in the presence of, e.g., an inverse agonist to the receptor, it is more likely that it will be able to more readily differentiate, particularly in the context of screening, between the receptor when it is contacted with the inverse agonist.

[0069] The GPCR Fusion Protein is intended to enhance the efficacy of G protein coupling with the non-endogenous GPCR. The GPCR Fusion Protein is preferred for screening with a non-endogenous, constitutively activated GPCR because such an approach increases the signal that is most preferably utilized in such screening techniques. This is important in facilitating a significant “signal to noise” ratio; such a significant ratio is preferred for the screening of candidate compounds as disclosed herein.

[0070] The construction of a construct useful for expression of a GPCR Fusion Protein is within the purview of those having ordinary skill in the art. Commercially available expression vectors and systems offer a variety of approaches that can fit the particular needs of an investigator. The criteria of importance for such a GPCR Fusion Protein construct is that the endogenous GPCR sequence and the G protein sequence both be in-frame (preferably, the sequence for the endogenous GPCR is upstream of the G protein sequence) and that the “stop” codon of the GPCR must be deleted or replaced such that upon expression of the GPCR, the G protein can also be expressed. The GPCR can be linked directly to the G protein, or there can be spacer residues between the two (preferably, no more than about 12, although this number can be readily ascertained by one of ordinary skill in the art). Use of a spacer is preferred (based upon convenience) in that some restriction sites that are not used will, effectively, upon expression, become a spacer. Most preferably, the G protein that couples to the non-endogenous GPCR will have been identified prior to the creation of the GPCR Fusion Protein construct. Because there are only a few G proteins that have been identified, it is preferred that a construct comprising the sequence of the G protein (i.e., a universal G protein construct) be available for insertion of an endogenous GPCR sequence therein; this provides for efficiency in the context of large-scale screening of a variety of different endogenous GPCRs having different sequences.

[0071] F. Co-Transfection of a Target Gi Coupled GPCR with a Signal-Enhancer Gs Coupled GPCR (cAMP Based Assays)

[0072] A Gi coupled receptor is known to inhibit adenylyl cyclase, and, therefore, decrease the level of cAMP production, which can make assessment of cAMP levels challenging. An effective technique in measuring the decrease in production of cAMP as an indication of constitutive activation of a receptor that predominantly couples Gi upon activation can be accomplished by co-transfecting a signal enhancer, e.g., a non-endogenous, constitutively activated receptor that predominantly couples with Gs upon activation (e.g., TSHR-A623I, disclosed below), with the Gi linked GPCR (such a technique is exemplified herein with the Gi coupled receptor, GPR24). As is apparent, constitutive activation of a Gs coupled receptor can be determined based upon an increase in production of cAMP. Constitutive activation of a Gi coupled receptor leads to a decrease in production cAMP. Thus, the co-transfection approach is intended to advantageously exploit these “opposite” affects. For example, co-transfection of a non-endogenous, constitutively activated Gs coupled receptor (the “signal enhancer”) with the endogenous Gi coupled receptor (the “target receptor”) provides a baseline cAMP signal (i.e., although the Gi coupled receptor will decrease cAMP levels, this “decrease” will be relative to the substantial increase in cAMP levels established by constitutively activated Gs coupled signal enhancer). By then co-transfecting the signal enhancer with a constitutively activated version of the target receptor, cAMP would be expected to further decrease (relative to base line) due to the increased functional activity of the Gi target (i.e., which decreases cAMP).

[0073] Screening of candidate compounds using a cAMP based assay can then be accomplished, with two provisos: first, relative to the Gi coupled target receptor, “opposite” effects will result, i.e., an inverse agonist of the Gi coupled target receptor will increase the measured cAMP signal, while an agonist of the Gi coupled target receptor will decrease this signal; second, as would be apparent, candidate compounds that are directly identified using this approach should be assessed independently to ensure that these do not target the signal enhancing receptor (this can be done prior to or after screening against the co-transfected receptors).

[0074] G. Medicinal Chemistry

[0075] Generally, but not always, direct identification of candidate compounds is preferably conducted in conjunction with compounds generated via combinatorial chemistry techniques, whereby thousands of compounds are randomly prepared for such analysis. Generally, the results of such screening will be compounds having unique core structures; thereafter, these compounds are preferably subjected to additional chemical modification around a preferred core structure(s) to further enhance the medicinal properties thereof. Such techniques are known to those in the art and will not be addressed in detail in this patent document.

[0076] H. Pharmaceutical Compositions

[0077] Candidate compounds selected for further development can be formulated into pharmaceutical compositions using techniques well known to those in the art. Suitable pharmaceutically-acceptable carriers are available to those in the art; for example, see Remington's Pharmaceutical Sciences, 16^(th) Edition, 1980, Mack Publishing Co., (Oslo et al., eds.).

[0078] I. Other Utility

[0079] Although a preferred use of the non-endogenous version of the known GPCRs disclosed herein may be for the direct identification of candidate compounds as inverse agonists, agonists or partial agonists (preferably for use as pharmaceutical agents), these versions of known GPCRs can also be utilized in research settings. For example, in vitro and in vivo systems incorporating GPCRs can be utilized to further elucidate and better understand the roles these receptors play in the human condition, both normal and diseased, as well as understanding the role of constitutive activation as it applies to understanding the signaling cascade. The value in non-endogenous known GPCRs is that their utility as a research tool is enhanced in that, because of their unique features, non-endogenous known GPCRs can be used to understand the role of these receptors in the human body before the endogenous ligand therefor is identified. Other uses of the disclosed receptors will become apparent to those in the art based upon, inter alia, a review of this patent document.

EXAMPLES

[0080] The following examples are presented for purposes of elucidation, and not limitation, of the present invention. While specific nucleic acid and amino acid sequences are disclosed herein, those of ordinary skill in the art are credited with the ability to make minor modifications to these sequences while achieving the same or substantially similar results as reported below. The traditional approach to application or understanding of sequence cassettes from one sequence to another (e.g. from rat receptor to human receptor or from human receptor A to human receptor B) is generally predicated upon sequence alignment techniques whereby the sequences are aligned in an effort to determine areas of commonality. The mutational approaches disclosed herein do not rely upon a sequence alignment approach but are instead based upon an algorithmic approach and a positional distance from a conserved proline residue located within the TM6 region of GPCRs. Once this approach is secured, those in the art are credited with the ability to make minor modifications thereto to achieve substantially the same results (i.e., constitutive activation) disclosed herein. Such modified approaches are considered within the purview of this disclosure

Example 1

[0081] Preparation of Endogenous Known GPCRS

[0082] A. Expression By Standard PCR

[0083] PCR was performed using a specific cDNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μM of each primer, and 0.2 mM of each 4 nucleotides.

[0084] The resulting PCR fragment was digested with the respective restriction sites and cloned into a pCMV expression vector. Nucleic acid and amino acid sequences were thereafter determined and verified. See Table D below: TABLE D 5′ Primer 3′ Primer Receptor Cycle Conditions (SEQ.ID.NO.) and (SEQ.ID.NO.) and Identifier Template Min (′), Sec (″) Restriction site Restriction site 5HT-1A Genomic DNA 94° for 1′ CGGAAGCTTAGC CCGGAATTCCTG 60° C. for 1′ CATGGATGTGCT GCGGCAGAAGTT 72° for 1′ 30″ CAGCCCTGGTCA ACACTTAATG (2); (1); HindIII EcoRI 5HT-1B Genomic DNA 94° for 1′ TCCAAGCTTGGG GGCGAATTCACTT 60° C. for 1′ GCGAGGAGAGCC GTGCACTTAAAA 72° for 1′30″ ATGGAGGA (3); CGTATCAGTT (4); HindIII EcoRI 5HT-1D Genomic DNA 94° for 1′ ATCTACCATGTC ATAGAATTCGGA 60° C. for 1′ CCCACTGAACCA GGCCTTCCGGAA 72° for 1′ 30″ GTCAGC (5) AGGGACAA (6); EcoRI 5HT-1E Genomic DNA 94° for 1′ CCACAGTGTCGA CAGTATGCTCTCG 60° C. for 1′ CTGAAACAAGGG GCATCTAATGAG 72° for 2′10″ AAACATGAAC (8) (7); SalI 5HT-1E Genomic DNA 94° for 1′ ATCACCATGGAT TTAGGATCCACAT 60° C. for 1′ TTCTTAAATTCAT CGACATCGCACA 72° for 2′ 10″ CTGATC (9) AGCTTTTG (10); BamHI 5HT-2B Uterus cDNA 94° for 1′ GAAAAGCTTGCC GTTGGATCCTACA 60° C. for 1′ ATGGCTCTCTCTT TAACTAACTTGCT 72° for 1′ 30″ ACAGAGTGTCTG CTTCAGTTT (12); (11); HindIII BamHI 5HT-4A Brain cDNA 94° for 1′ ATCACCATGGAC CCTGAATTCGAA 60° C. for 1′ AAACTTGATGCT GCATGATTCCAG 72° for 1′ 30″ AATGTGAG (13) GGATTCTGG (14); EcoRI 5HT-4B Brain cDNA 94° for 1′ ATCACCATGGAC AGGGAATTCAGT 60° C. for 1′ AAACTTGATGCT GTCACTGGGCTG 72° for 1′ 30″ AATGTGAG (15) AGCAGCCAC (16); EcoRI 5HT-4C Brain cDNA 94° for 1′ ATCACCATGGAC TTGGAATTCGGAT 60° for 1′ AAACTTGATGCT GGTTTGGTCAATC 72° for 1′ 30″ AATGTGAG (17) TTCTCTTC (18); EcoRI 5HT-4D 5HT-4E DNA 94° for 1′ ATCACCATGGAC AGGGAATTCAAA 60° C. for 1′ AAACTTGATGCT TCTTAGTACATGT 72° for 2″ AATGTGAG (19) GTGGATCCATTA AT (20); EcoRI 5HT-4E Brain cDNA 94° for 1′ ATCACCATGGAC TCAGAATTCGAC 60° C. for 1′ AAACTTGATGCT AGGAACTGGTCT 72° for 1′ 15″ AATGTGAG (21) ATTGCAGAA (22); EcoRI 5HT-5A Brain cDNA 94° for 1′ CCTAAGCTTGCC TCTGAATTCGTGT 60° C. for 1′ ATGGATTTACCA TGCCTAGAAAAG 72° for 2′ 10″ GTGAACCTAACC AAGTTCTTGA TCC (23); HindIII (24); EcoRI 5HT-6 See alternative See alternative See alternative See alternative approach below approach below approach below approach below 5HT-7 Brain cDNA 94° C. for 1′ AGCGGAATTCGG TTTCGGATCCATT 72° C. for 2″ CGGCGCGATGAT GTTCTGCTTTCAA GGACGTT (25); TCAT (26); BamHI EcoRI AVPR1A See alternative See alternative See alternative See alternative approach below approach below approach below approach below AVPR1A See alternative See alternative See alternative See alternative variant approach below approach below approach below approach below AVPR1B See alternative See alternative See alternative See alternative approach below approach below approach below approach below AVPR2 IMAGE 301449 pfu PCR CAGGAATTCAGA AGCGGATCCCGA 94° for 1′ ACACCTGCCCCA TGAAGTGTCCTTG 63° C. for 1′ GCCCCAC (27); GCCAGGGA (28); 72° for 2″ EcoRI BamHI BBR3 Uterus cDNA 94° C. for 1′ ACAGAATTCAGA CATGGATCCTTGA 56° for 1′ AGAAATGGCTCA AAAGCTAGAAAC 72° C. for 1′20″ AAGGCA (29); TGTCC (30); BamHI EcoRI BDKR1 IMAGE 1472696 pfu PCR TGTAAGCTTCAG GCTGGATCCATTC 94° for 1′ GTCACTGTGCAT CGCCAGAAAAGT 65° C. for 1′ GGCATCATC (31); TGGAAGATTTC 72° for 2″ HindIII (32); BamHI BDKR2 IMAGE 1682455 pfu PCR ACTAAGCTTCCA GTTGAATTCCTGT 94° for 1′ AATGTTCTCTCCC CTGCTCCCTGCCC 65° C. for 1′ TGGAAGATA (33) AGTCCTG (34); 72° for 2″ HindIII EcoRI C3a Genomic DNA 94° for 1′ CAGAAGCTTAGC ACAGGATCCCAC 65° C. for 1′ AATGGCGTCTTT AGTTGTACTATTT 72° for 1′ 30″ CTCTGCTG (35); CTTTCTGAAATG HindIII (36); BamHI C5a Thymus 94° for 1′ GGGAAGCTTAGG TGTGAATTCCACT 65° C. for 1′ AGACCAGAACAT GCCTGGGTCTTCT 72° for 1′ 10″ GAACTCCTTC GGGCCAT (38); (37); HindIII EcoRI CB1 EST 01536 pfu PCR GGGAAGCTTTCT TCAGAATTCCAG 94° for 1′ CAGTCATTTTGA AGCCTCGGCAGA 65° C. for 1′ GCTCAGCC (39); CGTGTCTGT (40); 72° for 2′ 30″ HindIII EcoRI CB2 IMAGE 1301708 pfu PCR CAAAAGCTTCTA GCCGAATTCGCA 94° for 1′ GACAAGCTCAGT ATCAGAGAGGTC 60° C. for 1′ GGAATCTGA (41); TAGATCTCTG 72° for 2″ HindIII (42); EcoRI CCR2b Genomic DNA 94° for 1′ GACAAGCTTCCC CTCGGATCCTAA 60° C. for 1′ CAGTACATCCAC ACCAGCCGAGAC 72° for 1′10″ AACATGC (43); TTCCTGCTC (44); HindIII BamHI CCR3 Genomic DNA 94° for 1′ ATCGCCATGACA TCTGAATTCAAAC 60° C. for 1′ ACCTCACTAGAT ACAATAGAGAGT 72° for 1′10″ ACAGTTGAG (45) TCCGGCTC (46); EcoRI CCR5 Genomic DNA 94° for 1′ GCAAAGCTTGGA TCCGGATCCCAA 62° C. for 1′ ACAAGATGGATT GCCCACAGATAT 72° for 1′10″ ATCAAGTGTC TTCCTGCTC (48); (47); HindIII BamHI CCR8 Genomic DNA 94° for 1′ TGAAAGCTTCCC TGAGAATTCCAA 60° C. for 1′ GCTGCCTTGATG AATGTAGTCTAC 72° for 1′10″ GATTATAC (49); GCTGGAGGAA HindIII (50); EcoRI CCR9 Genomic DNA 94° for 1′ ATCACCATGACA GACGAATTCGAG 60° C. for 1′ CCCACAGACTTC GGAGAGTGCTCC 72° for 1′10″ ACAAGCCCTATT TGAGGTTGT (52); CCTAACATGGCT EcoRI GATGACTATGG (51) CRFR1 Pituitary cDNA 94° for 1′ ATCACCATGGGA CGGGAATTCGAC 65° C. for 1′ GGGCACCCGCAG TGCTGTGGACTGC 72° for 1′20″ CTCCGT (53) TTGATGCT (54); EcoRI CXCR4 Genomic DNA 94° for 1′ ATCACCATGGAG TCTGAATTCGCTG 65° C. GGGATCAGTATA GAGTGAAAACTT 72° for 1′ TACACTTCAGAT GAAGACTCAG AACTACACCGAG (56); EcoRI GAAATG (55) Dopamine See alternative See alternative See alternative See alternative D1 approach below approach below approach below approach below Dopamine See alternative See alternative See alternative See alternative D2 approach below approach below approach below approach below Dopamine Brain cDNA 94° C. for 1′ AAGAAGCTTGGC GGCTCTAGAAAT D3 62° for 1′20″ ATCACGCACCTC GGGTACAAAGAG 72° C. for 1′20″ CTCTGG(57); TGTT (58); HindIII XbaI Dopamine Genomic DNA See alternative See alternative See alternative D5 approach below approach below approach below ETA See alternative See alternative See alternative See alternative approach below approach below approach below approach below ETB IMAGE 1086987 pfu PCR CGGAAGCTTCTG CTTGGATCCAGAT 94° for 1′ GAGCAGGTAGCA GAGCTGTATTTAT 60° C. for 1′ GCATG (59); TACTGGAACG 72° for 2′ 20″ HindIII (60); BamHI FPR1 IMAGE 2153284 94° C. for 1′ ATCACCATGGAG CCCGAATTCCTTT 63° for 1′ ACAAATTCCTCT GCCTGTAACTCCA 72° C. for 2′30″ CTCCCC (61) CCTCTGC (62); EcoRI FPRL1 Genomic DNA 94° C. for 1′ GCAAAGCTTGCT CCAGAATTCCATT 65° for 1′ GCTGGCAAGATG GCCTGTAACTCA 72° C. for 1′10″ GAAACCAAC (63); GTCTCTGC (64); HindIII EcoRI GALR1 Stomach cDNA 94° C. for 1′ CCGGAATTCGCC GCAGGATCCTTAT 60° for 1′20″ GGGACAGCCCCG CACACATGAGTA 72° C. for 1′20″ CGGGCC (65); CAATTGGT (66); EcoRI BamHI GALR2 Hippocampus 94° C. for 1′ GGCGAATTCGGG GTGGGATCCCAG cDNA 62° for 1′20″ GTCAGCGGCACC CGCGCCCGCTAA 72° C. for 1′20″ ATGAACG (67); GTGCT (68); BamHI EcoRI GIP Brain cDNA 94° for 1′ CAGAAGCTTCGC CGCGAATTCGCA 65° C. for 1′ CGCCCTCACGAT GTAACTTTCCAAC 72° for 1′30″ GACTAC (69); TCCCGGCT (70); HindIII EcoRI mGluR1 See alternative See alternative See alternative See alternative approach below approach below approach below approach below GPR5 Genomic DNA 94° C. for 1′ TATGAATTCAGA TCCGGATCCACCT 64° for 1′ TGCTCTAAACGT GCACCTGCGCCT 72° C. for 1′30″ CCCTGC (71); GCACC (72); BamHI EcoRI GPR24 (also See alternative See alternative See alternative See alternative known as approach below approach below approach below approach below MCH or SLC-1) GRPR Stomach cDNA 94° C. for 1′ AGGAAGCTTTTA CCGGAATTCAAG 56° for 1′20″ GGTGGGAAAAA GGGCAAAATCAA 65° C. for 1′20″ AAATCTA (73); GGGTCAA (74); HindIII EcoRI M1 Genomic DNA 94° C. for 1′ GCCAAGCTTAGC GGAGAATTCGCA 60° for 1′ CACCATGAACAC TTGGCGGGAGGG 72° C. for 1′50″ TTCAGCCC (75); AGTGCGGTG (76); HindIII EcoRI M2 Genomic DNA 94° C. for 1′ ATCACCATGAAT GATGAATTCCCTT 60° for 1′ AACTCAACAAAC GTAGCGCCTATGT 72° C. for 1′50″ TCCTCTAAC (77) TCTTATA (78); EcoRI M3 Genomic DNA 94° C. for 1′ ATCACCATGACC CTCGAAATTCCA 60° for 1′ TTGCACAATAAC AGGCCTGCTCGG 72° C. for 1′50″ AGTACAAC (79) GTGCGCGCT (80); EcoRI M4 Genomic DNA 94° C. for 1′ ATCACCATGGCC GCCGAATTCCCTG 60° for 1′ AACTTCACACCT GCAGTGCCGATG 72° C. for 1′50″ GTCAA (81) TTCCGATA (82); EcoRI M5 Genomic DNA 94° C. for 1′ ATCACCATGGAA GACGGATCCGGG 60° for 1′ GGGGATTCTTAC TAGCTTGCTGTTC 72° C. for 1′50″ CACAAT (83) CCCTGCCA (84); BamHI MC3 Genomic DNA 94° C. for 1′ CAGGAATTCTGA AATGGATCCTATC 54° for 1′30″ CAGCAATGAATG CCAAGTTCATGCC 72° C. for 1′20″ CTTCGT (85); GTTGCAG (86); EcoRI BamHI NK1R Brain cDNA 94° C. for 1′ AGTAAGCTTTAC TGTGAATTCGGA 65° for 1′ GCCTAGCTTCGA GAGCACATTGGA 72° C. for 1′50″ AATGGAT (87); GGAGAAGCT (88); HindIII EcoRI NK2R Uterus cDNA 94° C. for 1′ TCCAAGCTTAGA AACGAATTCAAT 65° for 1′ AGCAGCCATGGG TTCAACATGAGTT 72° C. for 1′50″ GACCTGTGACA TTGGTGGGGG (89); HindIII (90); EcoRI NK3R Brain cDNA 94° C. for 1′ ATCTGCAGACCG ATGGGATCCAGA 65° for 1′20″ GTGGCGATGGCC ATATTCATCCACA 72° C. for 1′20″ ACT (91) GAGGTATAGG (92); BamHI NMBR Brain cDNA 94° C. for 1′ TGAGAATTCCAG GTTGGATCCAGG 65° for 1′20″ CGGACTCTGCTG TAGTGAGTTGAA 72° C. for 1′20″ GAAAGGA (93); TGGCCA (94); EcoRI BamHI NPY5 Genomic DNA 94° C. for 1′ GGAAAGCTTCAA GGAGGATCCAGT 54° for 1′30″ GAAAGACTATAA GAGAATTATTAC 72° C. for 1′20″ TATGGAT (95); ATATGAAG (96); HindIII BamHI NTSR1 See alternative See alternative See alternative See alternative approach below approach below approach below approach below NTSR2 See alternative See alternative See alternative See alternative approach below approach below approach below approach below OPRD Brain cDNA 94° C. for 1′ CGGAAGCTTGCA GCCGAATTCGGC 65° for 1′ GCCATGGAACCG GGCAGCGCCACC 72° C. for 1′15 GCCCCCTCC (97); GCCGGGACC (98); HindIII EcoRI OPRL1 Brain cDNA 94° C. for 1′ AGTAAGCTTGCA GCCGAATTCTGC 65° for 1′ GGGCAGTGGCAT GGGCCGCGGTAC 72° C. for 1′15″ GGAGCCC (99); CGTCTCAGA (100); HindIII EcoRI OPRK Brain cDNA 94° C. for 1′ TTTAAGCTTGCA CTACTGGTTTATT 65° for 1′ GCACTCACCATG CATCCCATCGATG 72° C. for 1′15″ GAATCCCCGAT TC (102); (101); HindIII OPRM See alternative See alternative See alternative See alternative approach below approach below approach below approach below OPRM1A See alternative See alternative See alternative See alternative approach below approach below approach below approach below OX₁R See alternative See alternative See alternative See alternative approach below approach below approach below approach below OX₂R Brain cDNA 94° C. for 1′ ACCAAGCTTGAG CAGGGATCCTTGT 65° for 1′ CCCGTGATGTCC CATATGAATAAA 72° C. for 1′20″ GGCACC (103); TATT (104); BamHI HindIII PACAP Fetal Brain cDNA 94° C. for 1′ AGTAAGCTTGGC CATGAATTCGGT 65° for 1′ CAAGAAGTGTCA GGCCAGATTGTC 72° C. for 1′30″ TGGCTGGTG AGCAGGGAG (105); HindIII (106); EcoRI PAF Genomic DNA 94° C. for 1′ CTGAAGCTTCCA CAGGAATTCATTT 63° for 1′ GCCCACAGCAAT TTGAGGGAATTG 72° C. for 2′ 30″ GGAGCCA (107); CCAGGGATCTG HindIII (108); EcoRI PGE EP1 cDNA clone pfu PCR ATCGCCATGAGC TTGGAATTCGAA 94° C. for 1′ CCTTGCGGGCCC GTGGCTGAGGCC 63° for 1′ CTCAA (109) GCTGTGCCG (110); 72° C. for 2′30″ EcoRI PGE EP2 Thymus cDNA 94° C. for 1′ GCAAAGCTTTTC CTGGAATTCAAG 63° for 1′ CAGGCACCCCAC GTCAGCCTGTTTA 72° C. for 2′30″ CATGGGC (111); CTGGCATC (112); HindIII EcoRI PGE EP4 cDNA clone pfu PCR ATCATCATGTCC TGCGAATTCTATA 94° C. for 1′ ACTCCCGGGGTC CATTTTTCTGATA 60° for 1′ AAT (113) AGTTCAGTGTT 72° C. for 2′30″ (114); EcoRI PTHR1 See alternative See alternative See alternative See alternative approach below approach below approach below approach below PTHR2 Brain cDNA 94° C. for 1′ CTGAAGCTTCCT CGAGAACATCCT 65° for 1′ ACAGCCGTTCCG CAGTTTCTCCTTG 72° C. for 1′50″ GGCATG (115); G (116) HindIII SCTR Small Intestine 94° C. for 1′ GGGAAGCTTGCG AGCGAATTCGAT 65° for 1′ GGCACCATGCGT GATGCTGGTCCTG 72° C. for 1′45″ CCCCACCT (117); CAGGTGCC (118); HindIII EcoRI SST1 Genomic DNA 94° C. for 1′ GCCGAATTCAGC CAGGGATCCTGC 65° for 1′20″ TGGGATGTTCCC GTGGCCCGGGCT 72° C. for 1′20″ CAATGGC (119); CAGAGCG (120); EcoRI BamHI SST2 See alternative See alternative See alternative See alternative approach below approach below approach below approach below SST3 Genomic DNA 94° C. for 1′ ACGGAATTCCCC TGGGATCCCCAG 65° for 1′20″ TCAGCCATGGAC GCCCCTACAGGT 72° C. for 1′20″ ATGCTTC (121); AGCTG (122); EcoRI BamHI SST4 Genomic DNA 94° C. for 1′ GCCGAATTCAGC GAGGGATCCACG 65° for 1′20″ TGCCCTGCGCCG CAGGGTGGGTAG 72° C. for 1′20″ GCACCCC (123); GGGAAGG (124); EcoRI BamHI SST5 Genomic DNA 94° C. for 1′ TCTAAGCTTGCA CCTGAATTCCTGG 65° for 1′20″ GAGCCTGACGCA GGGTGACACGGG 72° C. for 1′20″ CCCCAG (125); GCCGCC (126); HindIII EcoRI TSHR Genomic DNA 94° C. for 1′ GGCGAATTCGGA GTAGGATCCCCT 65° for 1′ GGATGGAGAAAT ACCATTGTGAGT 72° C. for 2′30″ AGCCCC (127); AGTGTA (128); EcoRI BamHI VIPR1 Lung cDNA 94° C. for 1′ CCGAAGCTTCAG TGGGAATTCGAC 65° for 1′ GGCAGACCATGC CAGGGAGACTTC 72° C. for 1′30″ GCCCGCCA (129); GGCTTGGAA HindIII (130); EcoRI VIPR2 Brain cDNA 94° C. for 1′ GCTAAGCTTGCC GTGGAATTCGAT 65° for 1′ ATGCGGACGCTG GACCGAGGTCTC 72° C. for 1′30″ CTGCCTCCCGCG CGTTTGCAG (132); (131); HindIII EcoRI

[0085] B. Expression by Alternative Approaches

[0086] 1. AVPR1A

[0087] The endogenous human AVPR1A was obtained by PCR using a template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μM of each primer, and 0.2 mM of each 4 nucleotides. The cycle condition was 30 cycles of 94° C. for 1 min, 64° C. for 1 min and 72° C. for 1 min and 30 sec. The 5′ PCR fragment was obtained utilizing genomic DNA, as a template, and the following primer set: (SEQ.ID.NO.:133) 5′-ATCACCATGCGTCTCTCCGCCGGTCCCGA-3′ and (SEQ.ID.NO.:134) 5′-TTGTTCACCTCGATCATGGAGAAGA-3′-.

[0088] The 3′ PCR fragment was obtained by pfu polymerase (Stratagene) using IMAGE 1055179, as a template, and the following primer set: (SEQ.ID.NO.:135) 5′-CGCAGTACTTCGTCTTCTCCATGA-3′ and (SEQ.ID.NO.:136) 5′-CAAGAATTCAGTTGAAACAGGAATGAATTTGATGG-3′.

[0089] The cycle condition for 3′ PCR reaction was as follows: 30 cycles of 94° C. for 1 min, 60° C. and 72° C. for 1 min 30 sec. The 5′ and 3′ PCR fragments were then used as co-templates to obtain the full length cDNA using the pfu polymerase and SEQ.ID.NO.:133 and SEQ.ID.NO.:136 as primers. The cycle condition for each PCR reaction was 30 cycles of 94° C. for 1 min, 65° C. and 72° C. for 2 min 10 sec.

[0090] The resulting PCR fragment was digested with EcoRI restriction site and cloned into an EcoRI pCMV expression vector. Nucleic acid and amino acid sequences were thereafter determined and verified.

[0091] 2. AVPR1A Variant

[0092] The endogenous human AVPR1A variant was obtained by PCR using a template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μM of each primer, and 0.2 mM of each 4 nucleotides. The cycle condition was 30 cycles of 94° C. for 1 min, 64° C. for 1 min and 72° C. for 1 min and 30 sec. The 5′ PCR fragment was obtained utilizing genomic DNA, as a template, and: SEQ.ID.NO.:133 and SEQ.ID.NO.:134 as primers.

[0093] The 3′ PCR fragment was obtained by pfu polymerase (Stratagene) using IMAGE 1542469, as a template, and SEQ.ID.NO.:136 and 5′-ACAGAATTCTCCAGTTCTCATTTTCTTATCCGTAC-3′ (SEQ.ID.NO.:137).

[0094] The cycle condition for 3′ PCR reaction was as follows: 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 1 min 30 sec. The 5′ and 3′ PCR fragments were then used as co-templates to obtain the full length cDNA using the pfu polymerase (Stratagene) and SEQ.ID.NO.:133 and SEQ.ID.NO.:136 as primers. The cycle condition for each PCR reaction was 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 2 min 10 sec.

[0095] The resulting PCR fragment was digested with EcoRI restriction site and cloned into an EcoRI pCMV expression vector. Nucleic acid and amino acid sequences were thereafter determined and verified. 3. AVPR1B

[0096] The endogenous human AVPR1B was obtained by PCR using a template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μM of each primer, and 0.2 mM of each 4 nucleotides. Both rounds of PCR had the following cycle condition: 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 2 sec. The first round of PCR utilized a pituitary DNA, as a template, and a 5′ PCR primer that contained a HindIII site with the following sequence: 5′-GCAAAGCTTGCTCATGGATTCTGGGCCTCT-3′ (SEQ.ID.NO.:138) The 3′ PCR primer contained an EcoRI site with the following sequence: 5′-TCTGAATTCAAAGATGATGGTCTCAGCGGTGCC-3′-(SEQ.ID.NO.:139). The second round of PCR utilized pituitary DNA as a template and a 5′ PCR primer contained a HindIII site with the following sequence: 5′-GCAAAGCTTGCTCATGGATTCTGGGCCTCTGTGGG-3′ (SEQ.ID.NO.:140) and the 3′ PCR primer contained an EcoRI site with the following sequence: 5′-TCTGAATTCAAAGATGATGGTCTCAGCGGTGCCTTCCC-3′ (SEQ.ID.NO.:141).

[0097] The resulting PCR fragment was digested with HindIII and EcoRI restriction site and cloned into a HindIII-EcoRI pCMN expression vector. Nucleic acid and amino acid sequences were thereafter determined and verified.

[0098] 4. 5HT6

[0099] The endogenous human 5HT6 receptor was obtained by PCR using a template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μM of each primer, and 0.2 mM of each 4 nucleotides. Both rounds of PCR had the following cycle condition: 30 cycles of 94° C. for 1 min, 60° C. for 1 min and 72° C. for 1 min and 45 sec. The first round of PCR utilized a caudate nucleus DNA, as a template, and a 5′ PCR primer that contained a HindIII site with the following sequence: 5′-CATAAGCTTTCCCGCCACCCTATCACT-3′ (SEQ.ID.NO.:142) The 3′ PCR primer contained an EcoRI site with the following sequence: 5′-ACTGAATTCTGCTCAATCCAGCTCCCCA-3′-(SEQ.ID.NO.:143). The second round of PCR also utilized caudate nucleus DNA as a template and a 5′ PCR primer that contained an EcoRV site with the following sequence: 5′-CCTCGGATATCATGGTCCCAGAGCCGGGCCC-3′ (SEQ.ID.NO.:144) and a 3′ PCR primer that contained a XbaI site with the following sequence: 5′-CAGCTCTAGATTGGCCAGCCCCAAGCCCGGGT-3′ (SEQ.ID.NO.:145).

[0100] Nucleic acid and amino acid sequences were thereafter determined and verified.

[0101] 5. Dopamine D1

[0102] Dopamine D1 was subcloned from a full length cDNA clone obtained from the American Type Culture Collection.

[0103] 6. Dopamine D2

[0104] Dopamine D2 was subcloned from a full length cDNA clone obtained from the American Type Culture Collection.

[0105] 7. Dopamine D5

[0106] To obtain Dopamine D5, PCR was performed using genomic cDNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μM of each primer, and 0.2 mM of each 4 nucleotides.

[0107] Dopamine D5 receptor contained no intron in the coding region. However, Dopamine D5 receptor contained two pseudogenes with 8 bp fame shift insertion within the coding region. In order to avoid the pseudogenes, the DNA fragment 5′ and 3′ of the frame shift insert was each amplified from genomic DNA. The 5′ PCR fragment was obtained utilizing the following primer set: The 5′ PCR fragment was obtained utilizing the following primer set: 5′-CCTGAATTCCAGCCCGAAATGCTGCCGCCAG-3′ (SEQ.ID.NO.:146; sense) 5′-GGTCCACGCTGATGACGCACAGGTTC-3′ and (SEQ.ID.NO.:147; antisense) 3′ PCR fragment was obtained utilizing the following primer set: 5′-GAACCTGTGCGTCATCAGCGTGGACC-3′ (SEQ.ID.NO.: 148; sense) 5′-TGCGGATCCATGAGGGGGTTTCTTAATG-3′. (SEQ.ID.NO.:149; antisense)

[0108] The 5′ and 3′ PCR fragments were then used as co-templates to obtain the full length cDNA using the pfu polymerase and SEQ.ID.NO.:146 and SEQ.ID.NO.:149 as primers. The cycle condition for each PCR reaction was 30 cycles of 94° C. for 1 min, 65° C. for 2 min 30 sec and 72° C. for 1 min 30 sec.

[0109] The resulting PCR fragment was digested with EcoRI and Bamboo restriction sites and cloned into an EcoRI-BamHI pCMV expression vector. Nucleic acid and amino acid sequences were thereafter determined and verified.

[0110] 8. ETA

[0111] The endogenous human ETA was obtained by PCR using a template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μM of each primer, and 0.2 mM of each 4 nucleotides. The cycle condition was 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 2 sec. The 5′ PCR fragment, containing a HindIII site, was obtained utilizing genomic DNA, as a template, and the following primer set: (SEQ.ID.NO.:150) 5′-CGGAAGCTTCTGGAGCAGGTAGCAGCATG-3′ and (SEQ.ID.NO.:151) 5′-TGGGCAATAGTTGTGCATTGAGCCA-3′-.

[0112] The 3′ PCR fragment, containing BamHI site, was obtained by pfu polymerase (Stratagene) using IMAGE 666747, as a template, and the following primer set: (SEQ.ID.NO.:152) 5′-CTAATTTGGTCCTACCCAGCAATGGC-3′ and (SEQ.ID.NO.:153) 5′-CTTGGATCCAGATGAGCTGTATTTATTACTGGAACG-3′.

[0113] The cycle condition for 3′ PCR reaction was as follows: 30 cycles of 94° C. for 1 min, 64° C. for 1 min and 72° C. for 2 sec. The 5′ and 3′ PCR fragments were then used as co-templates to obtain the full length cDNA using the pfu polymerase (Stratagene) and the following primers: (SEQ ID.NO.:154) 5′-AATAAGCTTCAAGATGGAAACCCTTTGCCTCAG-3′ (SEQ.ID.NO.:155) 5′-CGTTCATGCTGTCCTTATGGCTGCTC-3′.

[0114] The PCR cycle condition for the full length clone was 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 2 min 10 sec.

[0115] The resulting PCR fragment was digested with EcoRI restriction site and cloned into an EcoRI pCMV expression vector. Nucleic acid and amino acid sequences were thereafter determined and verified.

[0116] 9. mGluR1

[0117] The endogenous human mGluR1 was obtained by PCR using a template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer. The cycle condition for the first round of PCR was as follows: 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 1 min and 50 sec. The 5′ PCR fragment contained a SalI site and was obtained utilizing hippocampus DNA as a template, and the following primer set: (SEQ.ID.NO.:156) 5′-GCAGGCTGTCGACCTCGTCCTCACCACCATGGTC-3′ and (SEQ.ID.NO.:157) 5′-AATGGGCTCACAGCCTGTTAGATCTGCATTGGGCCAC-3′-.

[0118] The middle PCR fragment was obtained utilizing genomic DNA as a template, where the cycle condition was 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 1 min and 50 sec, with the following primer set: (SEQ.ID.NO.:158) 5′-TAACAGGCTGTGAGCCCATTCCTGTGCG-3′ and (SEQ.ID.NO.:159) 5′-TTAGAATTCGCATTCCCTGCCCCTGCCTTCTTTC-3′.

[0119] The 3′ PCR fragment contained a BamHI site and was obtained utilizing genomic cDNA, as a template, and the following primer set: (SEQ.ID.NO.:160) 5′-TGCGAATTCTAATGGCAAGTCTGTGTCATGGTC-3′ and (SEQ.ID.NO.:161) 5′-TCCGGATCCCAGGGTGGAAGAGCTTTGCTTGTA-3′.

[0120] The cycle condition for 3′ PCR reaction was as follows: 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 1 min and 15 sec.

[0121] The resulting PCR fragment was digested with SalI and BamHI restriction site and cloned into a SalI-BamHI pCMV expression vector. Nucleic acid and amino acid sequences were thereafter determined and verified.

[0122] 10. GPR24 (Also Known as MCH or SLC-1)

[0123] The endogenous human GPR24 was obtained by PCR using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μM of each primer, and 0.2 mM of each 4 nucleotides. The cycle condition was 30 cycles of 94° C. for 1 min, 56° C. for 1 min and 72° C. for 1 min and 20 sec.

[0124] The 5′ PCR primer contained a HindIII site with the sequence: 5′-GTGAAGCTTGCCTCTGGTGCCTGCAGGAGG-3′ (SEQ.ID.NO.:162) and the 3′ primer contained an EcoRI site with the sequence: 5′-GCAGAATTCCCGGTGGCGTGTTGTGGTGCCC-3′ (SEQ.ID.NO.:163).

[0125] The 1.3 kb PCR fragment was digested with HindIII and EcoRI and cloned into HindIII-EcoRI site of CMVp expression vector. Later the cloning work by Lakaye et al showed that there is an intron in the coding region of the gene. Thus the 5′ end of the cDNA was obtained by 5′ RACE PCR using Clontech's marathon-ready hypothalamus cDNA as template and the manufacturer's recommended protocol for cycling condition. The 5′ RACE PCR for the first and second round PCR were as follows: 5′-CATGAGCTGGTGGATCATGAAGGG-3′ and (SEQ.ID.NO.:164) 5′-ATGAAGGGCATGCCCAGGAGAAAG-3′. (SEQ.ID.NO.:165)

[0126] Nucleic acid and amino acid sequences were thereafter determined and verified.

[0127] 11. NTSR1

[0128] The endogenous human NTSR1 was obtained by PCR using a template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μM of each primer, and 0.2 mM of each 4 nucleotides. The cycle condition was 30 cycles of 94° C. for 1 min, 60° C. for 1 min and 72° C. for 1 min and 10 sec. The 5′ PCR fragment, containing a HindIII site, was obtained utilizing genomic DNA, as a template, and the following primer set: (SEQ.ID.NO.:166) 5′-CCCAAGCTTCCAGCCCCGGAGGCGCCGGAC-3′ and (SEQ.ID.NO.:167) 5′-TGAAGGTGTTGACCTGTATGACGACCTTGACGGTGGG-3′-.

[0129] The 3′ PCR fragment, containing an EcoRI site, was obtained utilizing brain cDNA, as a template, and the following primer set: (SEQ.ID.NO.:168) 5′-GGTCGTCATACAGGTCAACACCTTCATGTCCTTCATA-3′ and (SEQ.ID.NO.:169) 5′-CACGAATTCGTACAGCGTCTCGCGGGTGGCATT-3′.

[0130] The cycle condition for 3′ PCR reaction was as follows: 30 cycles of 94° C. for 1 min, 60° C. for 1 min and 72° C. for 1 min and 10 sec. The 5′ and 3′ PCR fragments were then used as co-templates to obtain the full length cDNA using the pfu polymerase (Stratagene) and 5′-ATCACCATGCGCCTCAACAGCTCCGC-3′ (SEQ.ID.NO.:170) and SEQ.ID.NO.:169 as primers. The cycle condition for each PCR reaction was 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 2 min 10 sec.

[0131] The resulting PCR fragment was digested with HindIII and EcoRI restriction site and cloned into a HindIII-EcoRI pCMV expression vector. Nucleic acid and amino acid sequences were thereafter determined and verified.

[0132] 12. NTSR2

[0133] The endogenous human NTSR2 was obtained by PCR using a template and pfu polymerase (Stratagene) with the buffer system provided by the manufacturer. The cycle condition was 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 1 min and 15 sec. The 5′ PCR fragment was obtained utilizing IMAGE 1537523, as a template, and the following primer set: (SEQ.ID.NO.:171) 5′-ATCACCATGGAAACCAGCAGCCCGCGGC-3′ and (SEQ.ID.NO.:172) 5′-CGGGGTAGAAGTGGACGGCACTTGGG-3′-.

[0134] The 3′ PCR fragment, containing an EcoRI site, was obtained utilizing caudate nucleus cDNA, as a template, and the following primer set: (SEQ.ID.NO.:173) 5′-GCTCCCAAGTGCCGTCCACTTCTACC-3′ and (SEQ.ID.NO.:174) 5′-TTAGAATTCGGTCCGGGTTTCTGGGGGATCC-3′.

[0135] The cycle condition for 3′ PCR reaction was as follows: 30 cycles of 94° C. for 1 min, 60° C. for 1 min and 72° C. for 1 min and 20 sec. The 5′ and 3′ PCR fragments were then used as co-templates to obtain the full length cDNA using the pfu polymerase (Stratagene) and SEQ.ID.NO.:171 and SEQ.ID.NO.:174 as primers. The PCR cycle condition for the full length clone was 30 cycles of 94° C. for 1 min, 60° C. for 1 min and 72° C. for 2 min 10 sec.

[0136] The resulting PCR fragment was digested with EcoRI restriction site and cloned into an EcoRI pCMV expression vector. Nucleic acid and amino acid sequences were thereafter determined and verified.

[0137] 13. OPRM1

[0138] The endogenous human OPRM1 was obtained by PCR using a template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer. The cycle condition was 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 40 sec. The 5′ PCR fragment, containing a HindIII site, was obtained utilizing genomic DNA as a template, and the following primer set: (SEQ.ID.NO.:175) 5′-CCCAAGCTTCAGTACCATGGACAGCAGCGCTGCC-3′ and (SEQ.ID.NO.:176) 5′-CATCTTGGTGTATCTGACAATCACATACATGACCAGGAA-3′-.

[0139] The middle PCR fragment was obtained utilizing genomic DNA as a template, where the cycle condition was 30 cycles of 94° C. for 1 min, 60° C. for 1 min and 72° C. for 40 sec, and the following primer set: 5′-GTATGTGATTGTCAGATACACCAAGATGAAGACTGCCAC-3′ and (SEQ.ID.NO.:177) 5′-TACAATCTATGGAACCTTGCCTGTATTTTGTTGTAGCCA-3′. (SEQ.ID.NO.:178)

[0140] The 3′ PCR fragment was obtained utilizing brain cDNA, as a template, and the following primer set: 5′-CAAAATACAGGCAAGGTTCCATAGATTGTACACTAACAT-3′ and (SEQ.ID.NO.:179) 5′-CGGGCAACGGAGCAGTTTCTGCTTCAG-3′. (SEQ.ID.NO.: 180)

[0141] The cycle condition for 3′ PCR reaction was as follows: 30 cycles of 94° C. for 1 min, 63° C. for 1 min and 72° C. for 1 min and 15 sec.

[0142] The 5′PCR fragment and the middle PCR fragment were used as templates to obtain the 5′-region through the middle region of OPRM1 (“5′-middle PCR fragment”) using the pfu polymerase (Stratagene) and SEQ.ID.NO.:175 and SEQ.ID.NO.:178 with the cycle conditions as follows: 30 cycles of 94° C. for 1 min, 63° C. for 1 min and 72° C. for 1 min and 15 sec.

[0143] The 5′-middle PCR fragment and 3′ PCR fragment were then used as templates to obtain the full length cDNA using the pfu polymerase (Stratagene) and SEQ.ID.NO.:175 and SEQ.ID.NO.:180 as primers. The cycle condition for the full length PCR reaction was 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 1 min 15 sec.

[0144] The resulting PCR fragment was digested with Hindi restriction site and cloned into a HindIII pCMV expression vector. Nucleic acid and amino acid sequences were thereafter determined and verified.

[0145] 14. OPRM1A

[0146] The endogenous human OPRM1A was obtained by PCR using a template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer. The cycle condition was 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 40 sec. The 5′ PCR fragment, containing a HindIII site, was obtained utilizing genomic DNA as a template, and SEQ.ID.NO.:175 and SEQ.ID.NO.:176.

[0147] The middle PCR fragment was obtained utilizing genomic DNA as a template, where the cycle condition was 30 cycles of 94° C. for 1 min, 60° C. for 1 min and 72° C. for 40 sec, and SEQ.ID.NO.:177 and SEQ.ID.NO.:178.

[0148] The 3′ PCR fragment was obtained utilizing genomic DNA as a template, and SEQ.ID.NO.:179 and SEQ.ID.NO.:180. The cycle condition for 3′ PCR reaction was as follows: 30 cycles of 94° C. for 1 min, 60° C. for 1 min and 72° C. for 1 min and 30 sec.

[0149] The 5′PCR fragment and the middle PCR fragment were used as co-templates to obtain the 5′-region through the middle region of OPRM1A (“5′-middle PCR fragment”) using the pfu polymerase (Stratagene) and SEQ.ID.NO.:175 and SEQ.ID.NO.:178 with the cycle conditions as follows: 30 cycles of 94° C. for 1 min, 63° C. for 1 min and 72° C. for 1 min and 15 sec.

[0150] The 5′-middle PCR fragment and 3′ PCR fragment were then used as co-templates to obtain the full length cDNA using the pfu polymerase (Stratagene) and SEQ.ID.NO.:175 and SEQ.ID.NO.:180 as primers. The cycle condition for the full length PCR reaction was 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 1 min 15 sec.

[0151] The resulting PCR fragment was digested with HindIII restriction site and cloned into a HindIII pCMV expression vector. Nucleic acid and amino acid sequences were thereafter determined and verified.

[0152] 15. OX₁R

[0153] The OX₁R EST clone 40608 is a full length cDNA clone. However, it contained a 4 bp frame shift insertion. To remove the insert, the fragments 5, and 3, of the frame shift insert was each obtained by PCR using EST clone 40608 as template and two primer pairs. The 5′ primer set, containing an EcoRI site, were as follows: 5′-ATGGAATTCTGCTGCAGCGGCTCCTGAGCTC-3′ (SEQ.ID.NO.:181; sense) 5′-ACGGACACAGCCTGTAGATAGGGGATGACCTTGCAG-3′ (SEQ.ID.NO.:182; antisense) and the 3′ primer set, containing a BamHI site, were as follows: 5′-ATCCCCTATCTACAGGCTGTGTCCGTGTCAGTGGCAG-3′ (SEQ.ID.NO.:183; sense) 5′-GGAGGATCCAGGGCAGCCCTCGCTCAGGGC-3′. (SEQ.ID.NO.:184; antisense)

[0154] The 5′ and 3, PCR fragments were then used as cotemplates to obtain the full length cDNA using SEQ.ID.NO.:181 and SEQ.ID.NO.:184 as primers. The cycle condition for each PCR reaction was 30 cycles of 94° C. for 1 min, 65° C. for 2 min 30 sec and 72° C. for 1 min 30 sec.

[0155] The resulting PCR fragment was digested with EcoRI and BamHI restriction sites and cloned into an EcoRI-BamHI pCMV expression vector. Nucleic acid and amino acid sequences were thereafter determined and verified.

[0156] 16. PTHR1

[0157] The endogenous human PTHR1 was obtained by PCR using a template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer. The cycle condition was 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 1 min and 30 sec. The 5′ PCR fragment, containing a HindIII site, was obtained utilizing kidney cDNA, as a template, and the following primer set: (SEQ.ID.NO.:185) 5′-CGCAAGCTTAGGCGGTGGCGATGGGGACCGCC-3′ and (SEQ.ID.NO.:186) 5′-GGATGTGGTCCCATTCCGGCAGACAG-3′-.

[0158] The 3′ PCR fragment, containing an EcoRI site, was obtained by pfu PCR (Stratagene) and IMAGE 1624048, as a template, and the following primer set: (SEQ.ID.NO.:187) 5′-AGGAGGCACCCACTGGCAGCAGGTA-3′ and (SEQ.ID.NO.:188) 5′-GCCGAATTCCATGACTGTCTCCCACTCTTCCTG-3′.

[0159] The cycle condition for 3′ PCR reaction was as follows: 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 1 min and 30 sec. The 5′ and 3′ PCR fragments were then used as co-templates to obtain the full length cDNA using the pfu polymerase (Stratagene) and SEQ.ID.NO.:185 and SEQ.ID.NO.:188 as primers. The PCR cycle condition for the full length clone was 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 3 sec.

[0160] The resulting PCR fragment was digested with HindIII and EcoRI restriction site and cloned into a HindIII-EcoRI pCMV expression vector. Nucleic acid and amino acid sequences were thereafter determined and verified.

[0161] 17. SST2

[0162] SST2 was obtained by subcloning EST 06818 into a pCMN vector.

[0163] Table E below indicates the GenBank Accession number for which the endogenous receptors set forth above can be located, and for which the endogenous nucleic and amino acid sequences are provided. TABLE E Receptor Identifier GenBank Accession Number 5HT-1A X13556 5HT-1B D10995 5HT-1D M81589 5HT-1E M91467 5HT-1F L04962 5HT-2B X77307 5HT-4A Y08756 5HT-4B Y12505 5HT-4C Y12506 5HT-4D Y12507 5HT-4E AJ011371 5HT-5A X81411 5HT6 L41147 5HT7 L21195 AVPR1A AF030625 AVPR1B D31833 AVPR2 NM_000054 BBR3 X76498 BDKR1 AJ238044 BDKR2 NM_000623 C3a U62027 C5a M62505 CB1 X54937 CB2 X74328 CCR2b U03882 CCR3 U28694 CCR5 U54994 CCR8 U45983 CCR9 AJ132337 CRFR1 L23332 CXCR4 AJ224869 Dopamine D1 X55758 Dopamine D2 S62137 Dopamine D3 U32499 Dopamine D5 M67439 ETA X61950 ETB L06623 FPR1 M60627 FPRL1 M76672 GALR1 L34339 GALR2 AF040630 GALR3 AF073799 GIP U39231 mGluR1 L76627 GPR5 L36149 GPR24 (also known as MCH or SLC-1) U71092 GRPR M73481 M1 X15263 M2 X15264 M3 X15266 M4 X15265 M5 M80333 MC3 L06155 NK1R M74290 NK2R M57414 NK3R M89473 NMBR M73482 NPY5 U94320 NTSR1 X70070 NTSR2 Y10148 OPRD U07882 OPRL1 X77130 OPRK U11053 OPRM L25119 OPRM1A L25119 OX₁R AF041243 OX₂R AF041245 PACAP D17516 PAF S56396 PGE EP1 L22647 PGE EP2 U19487 PGE EP4 NM_000958 PTHR1 L04308 PTHR2 U25128 SCTR U28281 SST1 M81829 SST2 M81830 SST3 M96738 SST4 D16826 SST5 D16827 TSHR AF035261 VIPR L13288 VIPR2 X95097

Example 2

[0164] Preparation of Non-Endogenous, Versions of the Known GPCRS

[0165] A. Site-Directed Mutagenesis

[0166] Those skilled in the art are credited with the ability to select techniques for mutation of a nucleic acid sequence. Presented below are approaches utilized to create non-endogenous versions of several of the human GPCRs disclosed above. The mutations disclosed below are based upon an algorithmic approach whereby the 16^(th) amino acid (located in the IC3 region of the GPCR) from a conserved proline residue (located in the TM6 region of the GPCR, near the TM6/IC3 interface) is mutated, most preferably to a lysine amino acid residue.

[0167] In most of the examples of this Example 2, the algorithmic approach set forth above was used to identify the amino acid residue to be mutated. However, several GPCRs set forth below utilized a modified algorithmic approach (e.g., CRFR1, GIP, mGluR1, GPR24, PTHR1, PTHR2, SCTR, TSHR, VIPR and VIPR2). This modified approach focuses on a conserved proline residue (also located in the TM6 region of the GPCR, near the TM6/IC3 interface) whereby the 5^(th) amino acid upstream from the proline is generally, but not always, a threonine residue. For these receptors, the endogenous 5^(th) amino acid residue is mutated, most preferably to a proline amino acid residue.

[0168] Other mutation approaches can be used (e.g., mGluR1, GPR24 and TSHR) and one skilled in the art is credited with the ability to select techniques for mutation of a nucleic acid sequence. The importance here is that the mutation leads to a constitutively activated receptor and given the extension approaches set forth herein for determination of constitutively activity, routine analysis can be employed in this context.

[0169] Preparation of non-endogenous known GPCRs is preferably accomplished by using Transformer Site-Directed™ Mutagenesis Kit (Stratagene, according to manufacturer's instructions) or QuikChange Site-Directed™ Mutagenesis (Clontech). Endogenous GPCR is preferably used as a template and two mutagenesis primers utilized, as well as, most preferably, a lysine mutagenesis oligonucleotide and a selection marker oligonucleotide (SEQ.ID.NO.:252; included in Stratagene's kit). For convenience, the codon mutation incorporated into the known GPCR and the respective oligonucleotides are noted, in standard form (Table F): TABLE F 5′-3′ orientation (sense), Receptor Codon (SEQ.ID.NO.) mutation 5′-3′ orientation (antisense) Identifier Mutation underlined (SEQ.ID.NO.) 5HT-1A V343K CGAGAGAGGAAGACAAAG ATGCCCAGCGTCTTCTTT AAGACGCTGGGCAT (189) GTCTTCCTCTCTCG (190) 5HT-1B T313K GGGAGCGCAAAGCCAAGA GATCCCTAGGGTCTTCTT AGACCCTAGGGATC (191) GGCTTTGCGCTCCC (192) 5HT-1D T300K CGAGAAAGGAAAGCCAAG GAATGATGCCCAGGATT AAAATCCTGGGCATCATTC TTCTTGGCTTTCCTTTCT (193) CG(194) 5HT-1E A290K AGGGAACGGAAGGCAAAA AGCCCCAGGATGCGTTT CGCATCCTGGGGCT (195) TGCCTTCCGTTCCCT (196) 5HT-1F A292K CAAGAGAACGGAAAGCAA GATTAATCCCAGGGTAG AGACTACCCTGGGATTAAT TCTTTGCTTTCCGTTCTC C(197) TTG(198) 5HT-2B S323K AACGAACAGAGAGCCAAA CAATCCCTAGGACCTTTT AAGGTCCTAGGGATTG TGGCTCTCTGTTCGTT (199) (200) 5HT-4A A258K GGACAGAGACCAAAGCAA GATGCACAGGGTCTTCTT AGAAGACCCTGTGCATC TGCTTTGGTCTCTGTCC (201) (202) 5HT-4B A258K GGACAGAGACCAAAGCAA GATGCACAGGGTCTTCTT AGAAGACCCTGTGCATC TGCTTTGGTCTCTGTCC (203) (204) 5HT-4C A258K GGACAGAGACCAAAGCAA GATGCACAGGGTCTTCTT AGAAGACCCTGTGCATC TGCTTTGGTCTCTGTCC (205) (206) 5HT-4D A258K GGACAGAGACCAAAGCAA GATGCACAGGGTCTTCTT AGAAGACCCTGTGCATC TGCTTTGGTCTCTGTCC (207) (208) 5HT-4E A258K GGACAGAGACCAAAGCAA GATGCACAGGGTCTTCTT AGAAGACCCTGTGCATC TGCTTTGGTCTCTGTCC (209) (210) 5HT-5A A284K AAGGAGCAGCGGGCCAAG GATGCCCACCATGAGCT CTCATGGTGGGCATC (211) TGGCCCGCTGCTCCTT (212) 5HT-6 S267K CTGAAGGCCAAGCTTACGCT ATGCCCAGCGTAAGCTTG GGGCATCCTGCTGGGCA GCCTTCAGGGCCTTCCTG (213) CT (214) 5HT-7 A326K GAACAGAAAGCAAAGACCA CCCAGGGTGGTCTTTGCT CCCTGGGGATCATCGT (215) TTCTGTTCTCGCTTAAA (216) AVPR1A V290K GCCAAGATCCGCACGAAGA CGATCACAAAAGTCATCT AGATGACTTTTGTGATCG TCTTCGTGCGGATCTTGG (217) C(218) AVPR1B V280K GGCCAAGATCCGAACAAAG CGATGACAAAGGTCATCT AAGATGACCTTTGTCATC TCTTTGTTCGGATCTTGG (219) CC (220) AVPR2 V270K GCTGTGGCCAAGACTAAGA CACTAGCGTCATCCTCTT GGATGACGCTAGTG (221) AGTCTTGGCCACAGC (222) BBR3 270K CGAAAGAGAATTAAAAGAA AATACCGTTCTTTTAATT CGGTATTGGTGTTG (223) CTCTTTCGGGATTC (224) BDKR1 T249K GCCGCAAGGATAGCAAGAC GTGAGGATCAGCGCTTTG CAAAGCGCTGATCCTCAC GTCTTGCTATCCTTGCGG (225) C (226) BDKR2 T269K CGGAGAGGAGGGCCAAGGT ACCAGGACTAGCACCTTG GCTAGTCCTGGT (227) GCCCTCCTCTCCG (228) C3a F376K CGCCAAGTCTCAGAGCAAA CACCACGGCCACTCGCTT ACCAAGCGAGTGGCCGTGG GGTTTTGCTCTGAGACTT TG (229) GGCG (230) C5a L241K CGGTCCACCAAGACAAAGA TGCCACCACCACCTTCTT AGGTGGTGGTGGCA (231) TGTCTTGGTGGACCG (232) CB1 A342K CGCATGGACATTAGGTTAA TCAGGACCAGGGTCTTCT AGAAGACCCTGGTCCTGA TTAACCTAATGTCCATGC (233) G (234) CB2 A244K GGCTGGATGTGAGGTTGAA CACTAGCCCTAGGGTCTT GAAGACCCTAGGGCTAGTG CTTCAACCTCACATCCAG (235) CC (236) CCR2b V242K GAAGAGGCATAGGGCAAAG GGTGAAGATGACTCTCTT AGAGTCATCTTCACC (237) TGCCCTATGCCTCTTC (238) CCR3 I238K GTAAAAAAAAGTACAAGGC GATGACAAAAATGAGCC CAAGCGGCTCATTTTTGTCA GCTTGGCCTTGTACTTTTT TC (239) TTTAC (240) CCR5 V234K GAAGAGGCACAGGGCTAAG GATGGTGAAGATAAGCC AGGCTTATCTTCACCATC TCTTAGCCCTGTGCCTCT (241) TC (242) CCR8 I237K CCACAACAAGACCAAGGCC CCACAATGAGCACCAAC AAGAGGTTGGTGCTCATTGT CTCTTGGCCTTGGTCTTG GG (243) TTGTGG (244) CCR9 L253K TCCAAGCACAAAGCCAAAA GGACAGTGATGGTCACTT AAGTGACCATCACTGTCC TTTTGGCTTTGTGCTTGG (245) A (246) CRFR1 T316P GAAGGCTGTGAAAGCCCCT GCAGCAGCACCAGAGGG CTGGTGCTGCTGC (247) GCTTTCACAGCCTTC (248) CXCR4 L238K AGAAGCGCAAGGCCAAGAA TGAGGATGACTGTGGTCT GACCACAGTCATCCTCA TCTTGGCCTTGCGCTTCT (249) (250) Dopamine D1 L271K GAGAAACTAAAGTCAAGAA CTCCTTCGGTCCTCCTAT GACTCTGTG (251) CGTTGTCAGAAGT (252) Dopamine D2 T372K GAGAAGAAAGCCAATCAGA GGCGAGCATCTGAGTGG TGCTCGCC (253) CTTTCTTCTC (254) Dopamine D3 T328K GAGAAGAAGGCAAAACAAA GGCCACCATTTGTTTTGC TGGTGGCC (255) CTTCTTCTC (256) Dopamine D5 L295K AAGAAGGAGACCAAAGTTA CGACAGGGTCTTTTTAAC AAAAGACCCTGTCG (257) TTTGGTCTCCTTCTT (258) ETA A305K CAGCGTCGAGAAGTGAAAA TACAACCAAGCAGAAAA AAACAGTTTTCTGCTTGGTT CTGTTTTTTTCACTTCTCG GTA (259) ACGCTG (260) ETB A322K CAGAGACGGGAAGTGAAGA CCAGGCAAAAGACGGTT AAACCGTCTTTTGCCTGG TTCTTCACTTCCCGTCTCT (261) G(262) FPR1 L240K AAGTCCAGTCGTCCCAAAC AAGGAGAGGACCCGTTT GGGTCCTCTCCTT (263) GGGACGACTGGACTT (264) FPRL1 L240K AAATCCAGCCGTCCCAAAC GCAGTGAGGACCCGTTTG GGGTCCTCACTGC (265) GGACGGCTGGATTT (266) GALR1 A246K CCAAGAAAAAGACTAAACA CTCCTTCGGTCCTCCTAT GACAGTTCTGG (267) CGTTGTCAGAAGT (252) GALR2 T235K GCCAAGCGCAAGGTGAAAC GAGGATCATGCGTTTCAC GCATGATCCTC (268) CTTGCGCTTGGCG (269) GIP T343P AGGCTGGCTCGCTCCCCGCT GCACCAGCGTCAGCGGG GACGCTGGTGC (270) GAGCGAGCCAGCCT (271) mGluR1 3′ Deletion See alternative approach below See alternative approach below GPR5 V224K CGGCGCCACCGCACGAAAA CTCCTTCGGTCCTCCTAT AGCTCATCTTC (272) CGTTGTCAGAAGT (252) GPR24 (also T255K See alternative approach below See alternative approach known as MCH T255K/T257R below or SLC-1) 24-IC3-SST2 C305Y P271L W269C W269F W269L F265I 1261Q D140N GRPR A263K GGAAGCGACTTAAGAAGAC CAGCACTGTCTTCTTAAG AGTGCTGGTGTTT (273) TCGCTTCCGGGATTC (274) M1 A364K AAGGAGAAGAAGGCGAAAC GGCACTCAGGGTCCGTTT GGACCCTGAGTGCC (275) CGCCTTCTTCTCCTT (276) M2 T386K CCGGGAAAAGAAAGTCAAG AGCCAAGATTGTCCTCTT AGGACAATCTTGGCT (277) GACTTTCTTTTCCCGG (278) M3 A490K GGTCAAGGAGAAGAAAGCG CGCACTGAGGGTCTGTTT AAACAGACCCTCAGTGCG CGCTTTCTTCTCCTTGACC (279) (280) M4 T399K GGGAGCGCAAAGTGAAACG GGCAAAGATCGTTCGTTT AACGATCTTTGCC (281) CACTTTGCGCTCCC (282) M5 A441K GTCAAAGAGAGGAAAGCAA GGCACTCAGTGTCTGTTT AACAGACACTGAGTGCC TGCTTTCCTCTCTTTGAC (283) (284) MC3 A241K GCAACACTCATGTATGAAG CTCCTTCGGTCCTCCTAT GGGAAAGTCACCATCACC CGTTGTCAGAAGT (252) (285) NK1R V247K GCCAAGCGCAAGGTGAAGA GACAATCATCATTTTCTT AAATGATGATTGTC (286) CACCTTGCGCTTGGC (287) NK2R V249K GCCAAGAAGAAGTTTAAGA AGCACCATGGTCTTCTTA AGACCATGGTGCT (288) AACTTCTTCTTGGC (289) NK3R V298K GGCCAAAAGAAAGGTTAAG CAATAATCATCATTTTCT AAAATGATGATTATTG (290) TAACCTTTCTTTTGGCC (291) NMBR A265K CACGGAAACGCCTGAAAAA CAAGCACAATTTTTTTCA AATTGTGCTTG (292) GGCGTTTCCGTG (293) NPY5 F367K GAATAAAAAAGAGATCACG GGTCAGTCTGTACTTAAC AAGTGTTAAGTACAGACTG ACTTCGTGATCTCTTTTTT ACC (294) AT (295) NTSR1 V302K GCCCTGCGGCACGGCAAGC GCACGTAGGACGCGCTTG GCGTCCTACGTGC (296) CCGTGCCGCAGGGC (297) NTSR2 V269K AGCCTCCAGCGCAGCAAGC GGCTCTGAGAACCTGCTT AGGTTCTCAGAGCC (298) GCTGCGCTGGAGGCT (299) OPRD T260K GCCTGCGGCGCATCAAGCG ACCAGCACCATGCGCTTG CATGGTGCTGGT (300) ATGCGCCGCAGGC (301) OPRL1 T262K ACCTGCGGCGCATCAAGCG CACCAGCACCAGCCGCTT GCTGGTGCTGGTG (302) GATGCGCCGCAGGT (303) OPRK T273K ACCTGCGTAGGATCAAGAG CACCAGGACCAGTCTCTT ACTGGTCCTGGTG (304) GATCCTACGCAGGT (305) OPRM T281K GGGAATCTTCGAAGGATCA CACCAGCACCATCCTCTT AGAGGATGGTGCTGGTG GATCCTTCGAAGATTCC (306) (307) OPRM1A T281K GGGAATCTTCGAAGGATCA CACCAGCACCATCCTCTT AGAGGATGGTGCTGGTG GATCCTTCGAAGATTCC (308) (309) OX_(I)R A297K CGGAGGAAGACAAAAAAGA CCATCAGCATCTTTTTTG TGCTGATGG (310) TCTTCCTCCG (311) OX₂R A303K CCAGAAGGAAAACAAAACG CTCCTTCGGTCCTCCTAT GATGTTGATG (312) CGTTGTCAGAAGT (252) PACAP T355K CGACTGGCCCGGTCCCCCCT GGATGAGCAGCAGGGGG GCTGCTCATCC (313) GACCGGGCCAGTCG (314) PAF L231K GTCAAGCGCCGGGCGAAGT GTGCACACCATCCACTTC GGATGGTGTGCAC (315) GCCCGGCGCTTGAC (316) PGE EP1 V296K CACGACGTGGAGATGAAGG CCGACAAGCTGGCCCTTC GCCAGCTTGTCGG (317) ATCTCCACGTCGTG (318) PGE EP2 L263K GAGGAGACGGACCACAAGA CATGATAGCCAGGAGAA TTCTCCTGGCTATCATG (319) TCTTGTGGTCCGTCTCCT C (320) PGE EP4 V271K GCCGAGATCCAGATGAAGA GGTGGCAATGAGTAAGA TCTTACTCATTGCCACC (321) TCTTCATCTGGATCTCGG C (322) PTHR1 T410P GGAAGCTGCTCAAATCCCC GCATGAGCACCAGCGGG GCTGGTGCTCATGC (323) GATTTGAGCAGCTTCC (324) PTHR2 T365P GGAAACTGGCCAAATCGCC GGACCAGGACCAGTGGC ACTGGTCCTGGTCC (325) GATTTGGCCAGTTTCC (326) SCTR T344P CGCCTGGCCAGGTCCCCTCT GGATCAGCAGGAGAGGG CCTGCTGATCC (327) GACCTGGCCAGGCG (328) SST1 T270K CGAGCGCAAGATCAAATTA CTCCTTCGGTCCTCCTAT ATGGTGATGG (329) CGTTGTCAGAAGT (252) SST2 T255K AGAAGAAGGTCAAACGAAT GGACACCATTCGTTTGAC GGTGTCCATCGTG (330) CTTCTTCTCAGACT (331) SST3 T256K GAACGCAGGGTCAAGCGCA CTCCTTCGGTCCTCCTAT TGGTGGTGGCC (332) CGTTGTCAGAAGT (252) SST4 T258K CGGAGAAGAAAATCAAAAG CTCCTTCGGTCCTCCTAT GCTGGTGCTG (333) CGTTGTCAGAAGT (252) SST5 T247K TCGGAGCGAAAGGTGAAGC ACCATGCGCTTCACCTTT GCATGGTGTTGGTGGT (334) CGCTCCGAGCGCCGCCG (335) TSHR V509A See alternative approach below See alternative approach D619G below A6231 A623K C672Y D619G/A623K V509A/C672Y V509A/A623K/C672Y VIPR T343P AGGCTAGCCAGGTCCCCACT GGATCAGCAGGAGTGGG CCTGCTGATCC (336) GACCTGGCTAGCCT (337) VIPR2 T330P AGGCTGGCCAAGTCCCCGCT GGATAAGCAGGAGCGGG CCTGCTTATCC (338) GACTTGGCCAGCCT (339)

[0170] B. Alternative Approaches to Mutation

[0171] 1. mGluR1

[0172] Preparation of a non-endogenous version of the human mGluR1 receptor was accomplished by deleting a portion of the intracellular region at the 3′ end. The non-endogenous human mGluR1 was obtained by PCR using a template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer. The cycle condition for the first round of PCR was as follows: 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 1 min and 50 sec. The 5′ PCR fragment contained a SalI site and was obtained utilizing hippocampus DNA as a template, and the following primer set: (SEQ.ID.NO.:340) 5′-GCAGGCTGTCGACCTCGTCCTCACCACCATGGTC-3′ and (SEQ.ID.NO.:341) 5′-AATGGGCTCACAGCCTGTTAGATCTGCATTGGGCCAC-3′-.

[0173] The middle PCR fragment was obtained utilizing genomic DNA as a template, where the cycle condition was 30 cycles of 94° C. for 1 min, 65° C. for 1 min and 72° C. for 1 min and 50 sec, with the following primer set: (SEQ.ID.NO.:342) 5′-TAACAGGCTGTGAGCCCATTCCTGTGCG-3′ and (SEQ.ID.NO.:343) 5′-TTAGAATTCGCATTCCCTGCCCCTGCCTTCTTTC-3′.

[0174] The 3′ PCR fragment was obtained by utilizing the endogenous mGluR1 clone as a co-template to obtain the full length cDNA using the pfu polymerase. The cycle condition for this PCR reaction was 30 cycles of 94° C. for 1 min, 65° C. for 2 min 30 sec and 72° C. for 1 min 30 sec. and the following primer set: (SEQ.ID.NO.:344) 5′-TGCGAATTCTAATGGCAAGTCTGTGTCATGGTC-3′ and (SEQ.ID.NO.:345) 5′-TGCGGATCCTCTTCGGAAGATGTTGAGGAAAGTG-3′.

[0175] (See, SEQ.ID.NO.:346 for nucleic acid sequence and SEQ.ID.NO.:347 for amino acid sequence).

[0176] 2. GPR24 (MCH or SLC-1)

[0177] Preparation of non-endogenous versions of the human GPR24 receptor was accomplished by creating an T255K mutation (see, SEQ.ID.NO.:350 for nucleic acid sequence, SEQ.ID.NO.:351 for amino acid sequence), a T255K/T257R mutation (see, SEQ.ID.NO.:354 for nucleic acid sequence, SEQ.ID.NO.:355 for amino acid sequence), an 24-IC3-SST3 mutation (see, SEQ.ID.NO.:358 for nucleic acid sequence, SEQ.ID.NO.:359 for amino acid sequence), a C305Y mutation (see, SEQ.ID.NO.:362 for nucleic acid sequence, SEQ.ID.NO.:363 for amino acid sequence), a P271L mutation (see, SEQ.ID.NO.:366 for nucleic acid sequence, SEQ.ID.NO.:367 for amino acid sequence), a W269C mutation (see, SEQ.ID.NO.:370 for nucleic acid sequence, SEQ.ID.NO.:371 for amino acid sequence), a W269F mutation see, SEQ.ID.NO.:374 for nucleic acid sequence, SEQ.ID.NO.:375 for amino acid sequence), and a W269L mutation (see, SEQ.ID.NO.:378 for nucleic acid sequence, SEQ.ID.NO.:379 for amino acid sequence), a F265I mutation see, SEQ.ID.NO.:382 for nucleic acid sequence, SEQ.ID.NO.:383 for amino acid sequence), an I261Q mutation see, SEQ.ID.NO.:386 for nucleic acid sequence, SEQ.ID.NO.:387 for amino acid sequence), and a D140N mutation see, SEQ.ID.NO.:390 for nucleic acid sequence, SEQ.ID.NO.:391 for amino acid sequence).

[0178] A. T255K Mutation

[0179] Preparation of a non-endogenous version of the human GPR24 receptor was accomplished by creating an T255K mutation (see, SEQ.ID.NO.:350 for nucleic acid sequence, and SEQ.ID.NO.:351 for amino acid sequence). Mutagenesis was performed using Transformer Site-Directed Mutagenesis Kit (Clontech) according to the manufacturer. The PCR sense mutagenesis primer used had the following sequence: 5′-AGAGGGTGAAACGCACAGCCATCGCCATCTG-3′ (SEQ.ID.NO.:348) and the antisense primer (selection marker) had the following sequence: 5‘-CTCCTTCCGGTCCTCCTATCGTTGTCAGAAGT-3′ (SEQ.ID.NO.:349). The endogenous GPR24 cDNA was used as a template.

[0180] B. T255K/T257R Mutation

[0181] Preparation of a non-endogenous version of the human GPR24 receptor was accomplished by creating an T255K/T257R mutation (see, SEQ.ID.NO.:354 for nucleic acid sequence, and SEQ.ID.NO.:355 for amino acid sequence). Mutagenesis was performed using QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer. The PCR sense mutagenesis primer used had the following sequence: 5′-AGAGGGTGAAACGCAGAGCCATCGCCATCTG-3′ (SEQ.ID.NO.:352) and the antisense primer had the following sequence: 5′-CAGATGGCGATGGCTCTGCGTTTCACCCTCT-3′ (SEQ.ID.NO.:353). The endogenous GPR24 cDNA was used as a template.

[0182] C. 24-IC3-SST2 Mutation

[0183] Preparation of a non-endogenous version of the human GPR24 receptor was accomplished by creating a 24-IC3-SST2 mutation (see; SEQ.ID.NO.:358 for nucleic acid sequence, and SEQ.ID.NO.:359 for amino acid sequence). Blast result showed that GPR24 had the highest sequence homology to SST2. Thus the IC3 loop of GPR24 was replaced with that of SST2 to see if the chimera would show constitutive activity.

[0184] The BamHI-BstEII fragment containing IC3 of GPR24 was replaced with synthetic oligonucleotides that contained the IC3 of SST2. The PCR sense mutagenesis primer used had the following sequence: 5′-GATCCTGCAGAAGGTGAAGTCCTCTGGAATCCGAGTGGGCTCCTCTAAGAGGAAGAAGTCTGAGAAGAAG-3′ (SEQ.ID.NO.:356)

[0185] and the antisense primer had the following sequence: 5′-GTGACCTTCTTCTCAGACTTCTTCCTCTTAGAGGAGCCCACTCGGATTCCAGAGGACTTCACCTTCTGCAG-3′. (SEQ.D.NO.:357)

[0186] The endogenous GPR24 cDNA was used as a template.

[0187] D. C305Y Mutation

[0188] Preparation of a non-endogenous version of the human GPR24 receptor was accomplished by creating an C305Y mutation (see, SEQ.ID.NO.:362 for nucleic acid sequence, and SEQ.ID.NO.:363 for amino acid sequence). Mutagenesis was performed using QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer. The PCR sense mutagenesis primer used had the following sequence: 5′-GGCTATGCCAACAGCTACCTCAACCCCTTTGTG-3′ (SEQ.ID.NO.:360) and the antisense primer had the following sequence: 5′-CACAAAGGGGTTGAGGTAGCTGTTGGCATAGCC-3′ (SEQ.ID.NO.:361). The endogenous GPR24 cDNA was used as a template.

[0189] E. P271L Mutation

[0190] Preparation of a non-endogenous version of the human GPR24 receptor was accomplished by creating an P271L mutation (see, SEQ.ID.NO.:366 for nucleic acid sequence, and SEQ.ID.NO.:367 for amino acid sequence). Mutagenesis was performed using QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer. The PCR sense mutagenesis primer used had the following sequence: 5′-TTGTGTGCTGGGCACTCTACTATGTGCTACAGC-3′ (SEQ.ID.NO.:364) and the antisense primer had the following sequence: 5′-GCTGTAGCACATAGTAGAGTGCCCAGCACACAA-3′ (SEQ.ID.NO.:365). The endogenous GPR24 cDNA was used as a template.

[0191] F. W269C Mutation

[0192] Preparation of a non-endogenous version of the human GPR24 receptor was accomplished by creating an W269C mutation (see, SEQ.ID.NO.:370 for nucleic acid sequence, and SEQ.ID.NO.:371 for amino acid sequence). Mutagenesis was performed using QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer. The PCR sense mutagenesis primer used had the following sequence: 5′-GGTCTTCTTTGTGTGCTGCGCACCCTACTATGTG-3′ (SEQ.ID.NO.:368) and the antisense primer had the following sequence: 5′-CACATAGTAGGGTGCGCAGCACACAAAGAAGACC-3′ (SEQ.ID.NO.:369). The endogenous GPR24 cDNA was used as a template.

[0193] G. W269F Mutation

[0194] Preparation of a non-endogenous version of the human GPR24 receptor was accomplished by creating an W269F mutation (see, SEQ.ID.NO.:374 for nucleic acid sequence, and SEQ.ID.NO.:375 for amino acid sequence). Mutagenesis was performed using QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer. The PCR sense mutagenesis primer used had the following sequence: 5′-GGTCTTCTTTGTGTGCTTCGCACCCTACTATGTG-3′ (SEQ.ID.NO.:372) and the antisense primer had the following sequence: 5′-CACATAGTAGGGTGCGAAGCACACAAAGAAGACC-3′ (SEQ.ID.NO.:373). The endogenous GPR24 cDNA was used as a template.

[0195] H. W269L Mutation

[0196] Preparation of a non-endogenous version of the human GPR24 receptor was accomplished by creating an W269L mutation (see, SEQ.ID.NO.:378 for nucleic acid sequence, and SEQ.ID.NO.:379 for amino acid sequence). Mutagenesis was performed using QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer. The PCR sense mutagenesis primer used had the following sequence: 5′-GGTCTTCTTTGTGTGCTTGGCACCCTACTATGTG-3′ (SEQ.ID.NO.:376) and the antisense primer had the following sequence: 5′-CACATAGTAGGGTGCCAAGCACACAAAGAAGACC-3′ (SEQ.ID.NO.:377). The endogenous GPR24 cDNA was used as a template.

[0197] I. F265I Mutation

[0198] Preparation of a non-endogenous version of the human GPR24 receptor was accomplished by creating an F265 I mutation (see, SEQ.ID.NO.:382 for nucleic acid sequence, and SEQ.ID.NO.:383 for amino acid sequence). Mutagenesis was performed using QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer. The PCR sense mutagenesis primer used had the following sequence: 5′-GCCATCTGTCTGGTCATCTTTGTGTGCTGGG-3′ (SEQ.ID.NO.:380) and the antisense primer had the following sequence: 5′-CCCAGCACACAAAGATGACCAGACAGATGGC-3′ (SEQ.ID.NO.:381). The endogenous GPR24 cDNA was used as a template.

[0199] J. I261Q Mutation

[0200] Preparation of a non-endogenous version of the human GPR24 receptor was accomplished by creating an I 261Q mutation (see, SEQ.ID.NO.:386 for nucleic acid sequence, and SEQ.ID.NO.:387 for amino acid sequence). Mutagenesis was performed using QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer. The PCR sense mutagenesis primer used had the following sequence: 5′-CGCACAGCCATCGCCCAGTGTCTGGTCTTCTTTGTG-3′ (SEQ.ID.NO.:384) and the antisense primer had the following sequence: 5′-CACAAAGAAGACCAGACACTGGGCGATGGCTGTGCG-3′ (SEQ.ID.NO.:385). The endogenous GPR24 cDNA was used as a template.

[0201] K. D140N Mutation

[0202] Preparation of a non-endogenous version of the human GPR24 receptor was accomplished by creating an D140N mutation (see, SEQ.ID.NO.:390 for nucleic acid sequence, and SEQ.ID.NO.:391 for amino acid sequence). Mutagenesis was performed using QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer. The PCR sense mutagenesis primer used had the following sequence: 5′-ACCGCCATGGCCATTAACGCGTACCTGGCCACT-3′ (SEQ.ID.NO.:388) and the antisense primer had the following sequence: 5′-AGTGGCCAGGTAGCGGTTAATGGCCATGGCGGT-3′ (SEQ.ID.NO.:389). The endogenous GPR24 cDNA was used as a template.

[0203] 3. TSHR

[0204] Preparation of non-endogenous versions of the human TSHR receptor were accomplished by creating an V509A mutation (see, SEQ.ID.NO.:394 for nucleic acid sequence, SEQ.ID.NO.:395 for amino acid sequence), a D619G mutation (see, SEQ.ID.NO.:398 for nucleic acid sequence, SEQ.ID.NO.:399 for amino acid sequence), an A623I mutation (see, SEQ.ID.NO.:402 for nucleic acid sequence, SEQ.ID.NO.:403 for amino acid sequence), a A623K mutation (see, SEQ.ID.NO.:406 for nucleic acid sequence, SEQ.ID.NO.:407 for amino acid sequence), an C672Y mutation (see, SEQ.ID.NO.:410 for nucleic acid sequence, SEQ.ID.NO.:411 for amino acid sequence), a D619G/A623K mutation (see, SEQ.ID.NO.:414 for nucleic acid sequence, SEQ.ID.NO.:415 for amino acid sequence), an V509A/C672Y mutation see, SEQ.ID.NO.:418 for nucleic acid sequence, SEQ.ID.NO.:419 for amino acid sequence), and an V509A/A623K/C672Y mutation (see, SEQ.ID.NO.:422 for nucleic acid sequence, SEQ.ID.NO.:423 for amino acid sequence).

[0205] A. V509A Mutation

[0206] Preparation of a non-endogenous version of the human TSHR receptor was accomplished by creating an V509A mutation (see, SEQ.ID.NO.:394 for nucleic acid sequence, and SEQ.ID.NO.:395 for amino acid sequence). Mutagenesis was performed using QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer. The PCR sense mutagenesis primer used had the following sequence: 5′-CAAGCGAGTTATCGGCATATACGCTGACGGTC-3′ (SEQ.ID.NO.:392) and the antisense primer had the following sequence: 5′-GACCGTCAGCGTATATGCCGATAACTCGCTTG-3′ (SEQ.ID.NO.:393). The endogenous TSHR cDNA was used as a template. This V509A mutant can be differentiated from the endogenous version by the absence of an AccI site near the mutation site.

[0207] B. D619G Mutation

[0208] Preparation of a non-endogenous version of the human TSHR receptor was also accomplished by creating a D619G mutation (see, SEQ.ID.NO.:398 for nucleic acid sequence, and SEQ.ID.NO.:399 for amino acid sequence). Mutagenesis was performed using QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer. The PCR sense mutagenesis primer used had the following sequence: 5′-ACCCAGGGGACAAAGGTACCAAAATTGCCAA-3′ (SEQ.ID.NO.:396) and the antisense primer had the following sequence: 5′-TTGGCAATTTTGGTACCTTTGTCCCCTGGGT-3′ (SEQ.ID.NO.:397). The endogenous TSHR cDNA was used as a template. This D619G mutant can be differentiated from the endogenous version by the presence of a KpnI site near the mutation site.

[0209] C. A623I Mutation

[0210] Preparation of a non-endogenous version of the human TSBR was accomplished by creating an A623I mutation (see, SEQ.ID.NO.:402 for nucleic acid sequence, and SEQ.ID.NO.:403 for amino acid sequence). Mutagenesis was performed using QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer. The PCR sense mutagenesis primer used had the following sequence: 5′-AAAGATACCAAAATTATCAAGAGGATGGCTGT-3′ (SEQ.ID.NO.:400) and the antisense primer had the following sequence: 5′-ACAGCCATCCTCTTGATAATTTTGGTATCTTT-3′ (SEQ.ID.NO.:401). The endogenous TSHR cDNA was used as a template. This A623I mutant can be differentiated from the endogenous version by the absence of a BstXI site near the mutation site.

[0211] D. A623K Mutation

[0212] Preparation of a non-endogenous version of the human TSHR receptor was also accomplished by creating a A623K mutation (see, SEQ.ID.NO.:406 for nucleic acid sequence, and SEQ.ID.NO.:407 for amino acid sequence). Mutagenesis was performed using QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer. The PCR sense mutagenesis primer used had the following sequence: 5′-AAAGATACCAAAATTAAGAAGAGGATGGCTGTG-3′ (SEQ.ID.NO.:404) and the antisense primer had the following sequence: 5′-CACAGCCATCCTCTTCTTAATTTTGGTATCTTT-3′ (SEQ.ID.NO.:405). The endogenous TSHR cDNA was used as a template. This A623K mutant can be differentiated from the endogenous version by the absence of a BstXI site near the mutation site.

[0213] E. C672Y Mutation

[0214] Preparation of a non-endogenous version of the human TSHR receptor was also accomplished by creating a C672Y mutation (see, SEQ.ID.NO.:410 for nucleic acid sequence, and SEQ.ID.NO.:411 for amino acid sequence). Mutagenesis was performed using QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer. The PCR sense mutagenesis primer used had the following sequence: 5′-CTATCCACTTAACTCGTACGCCAATCCATTCCTC-3′ (SEQ.ID.NO.:408) and the antisense primer had the following sequence: 5′-GAGGAATGGATTGGCGTACGAGTTAAGTGGATAG-3′ (SEQ.ID.NO.:409). The endogenous TSIR cDNA was used as a template. This C672Y mutant can be differentiated from the endogenous version by the presence of a BsiWI site near the mutation site.

[0215] F. D619G/A623K Mutation

[0216] Preparation of a non-endogenous version of the human TSHR receptor was also accomplished by creating a D619G/A623K mutation (see, SEQ.ID.NO.:414for nucleic acid sequence, and SEQ.ID.NO.:415 for amino acid sequence). Mutagenesis was performed using QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer. The PCR sense mutagenesis primer used had the following sequence: 5′-ACCCAGGGGACAAAGGTACCAAAATTAAGAAGAGGATGGCTGTG-3′ (SEQ.ID.NO.:412)

[0217] and the antisense primer had the following sequence: 5′-CACAGCCATCCTCTTCTTAATTTTGGTACCTTTGTCCCCTGGGT-3′ (SEQ.ID.NO.:413). The non-endogenous D619G mutant version of TSHR cDNA was used as a template. This D619G/A623K mutant can be differentiated from the endogenous version by the presence of a KpnI site near the D619G mutation site and absence of a BstXI site near the A623K mutation site.

[0218] G. V509A/C672Y Mutation

[0219] Preparation of a non-endogenous version of the human TSHR receptor was also accomplished by creating a V509A/C672Y mutation (see, SEQ.ID.NO.:418 for nucleic acid sequence, and SEQ.ID.NO.:419 for amino acid sequence). Mutagenesis was performed using QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer. The V509A sense mutagenesis primer used had the following sequence: 5′-CAAGCGAGTTATCGGCATATACGCTGACGGTC-3′ (SEQ.ID.NO.:416) and the C672Y antisense primer had the following sequence: 5′-GAGGAATGGATTGGCGTACGAGTTAAGTGGATAG-3′ (SEQ.ID.NO.:417). The endogenous TSHR cDNA was used as a template. This V509A/C672Y mutant can be differentiated from the endogenous version by the absence of an AccI site near the V509A mutation site and presence of a BsiWI site near the C672Y mutation site.

[0220] H. V509A/A623K/C672Y Mutation

[0221] Preparation of a non-endogenous version of the human TSHR receptor was also accomplished by creating a V509A/A623K/C672Y mutation (see, SEQ.ID.NO.:422 for nucleic acid sequence, and SEQ.ID.NO.:423 for amino acid sequence). Mutagenesis was performed using QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer. The A623K sense mutagenesis primer used had the following sequence: 5′-AAAGATACCAAAATTAAGAAGAGGATGGCTGTG-3′ (SEQ.ID.NO.:420) and the A623K antisense primer had the following sequence: 5′-CACAGCCATCCTCTTCTTAATTTTGGTATCTTT-3′ (SEQ.ID.NO.:421). The non-endogenous V509A/C672Y mutant version of TSHR cDNA was used as a template. This V509A/A623K/C672Y mutant can be differentiated from the endogenous version by the absence of an AccI site near the V509A mutation site, absence of a BstXI near the A623K mutation site and the presence of a BsiWI site near the C672Y mutation 10 site.

[0222] The non-endogenous human GPCRs were then sequenced and the derived and verified nucleic acid and amino acid sequences are listed in the accompanying “Sequence Listing” appendix to this patent document, as summarized in Table G below: TABLE G Nucleic Acid Sequence Amino Acid Sequence Mutated GPCR Listing Listing 5HT-1A SEQ.ID.NO.:424 SEQ.ID.NO.:425 V343K 5HT-1B SEQ.ID.NO.:426 SEQ.ID.NO.:427 T313K 5HT-1D SEQ.ID.NO.:428 SEQ.ID.NO.:429 T300K 5HT-1E SEQ.ID.NO.:430 SEQ.ID.NO.:431 A290K 5H7-1F SEQ.ID.NO.:432 SEQ.ID.NO.:433 A292K 5HT-2B SEQ.ID.NO.:434 SEQ.ID.NO.:435 S323K 5H17-4A SEQ.ID.NO.:436 SEQ.ID.NO.:437 A258K 5HT-4B SEQ.ID.NO.:438 SEQ.ID.NO.:439 A258K 5HT-4C SEQ.ID.NO.:440 SEQ.ID.NO.:441 A258K 5HT-4D SEQ.ID.NO.:442 SEQ.ID.NO.:443 A258K 5HT-4E SEQ.ID.NO.:444 SEQ.ID.NO.:445 A258K 5HT-5A SEQ.ID.NO.:446 SEQ.ID.NO.:447 A284K 5HT-6 SEQ.ID.NO.:448 SEQ.ID.NO.:449 S267K 5HT-7 SEQ.ID.NO.:450 SEQ.ID.NO.:451 A326K AVPR1A SEQ.ID.NO.:452 SEQ.ID.NO.:453 V290K AVPR1B SEQ.ID.NO.:454 SEQ.ID.NO.:455 V280K AVPR2 SEQ.ID.NO.:456 SEQ.ID.NO.:457 V270K BBR3 SEQ.ID.NO.:458 SEQ.ID.NO.:459 A270K BDKR1 SEQ.ID.NO.:460 SEQ.ID.NO.:461 T249K BDKR2 SEQ.ID.NO.:462 SEQ.ID.NO.:463 T269K C3a SEQ.ID.NO.:464 SEQ.ID.NO.:465 F376K C5a SEQ.ID.NO.:466 SEQ.ID.NO.:467 L241K CB1 SEQ.ID.NO.:468 SEQ.ID.NO.:469 A342K CB2 SEQ.ID.NO.:470 SEQ.ID.NO.:471 A244K CCR2b SEQ.ID.NO.:472 SEQ.ID.NO.:473 V242K CCR3 SEQ.ID.NO.:474 SEQ.ID.NO.:475 I238K CCR5 SEQ.ID.NO.:476 SEQ.ID.NO.:477 V234K CCR8 SEQ.ID.NO.:478 SEQ.ID.NO.:479 1237K CCR9 SEQ.ID.NO.:480 SEQ.ID.NO.:481 L253K CRFR1 SEQ.ID.NO.:482 SEQ.ID.NO.:483 T316P CXCR4 SEQ.ID.NO.:484 SEQ.ID.NO.:485 L238K Dopamine D1 SEQ.ID.NO.:486 SEQ.ID.NO.:487 L271K Dopamine D2 SEQ.ID.NO.:488 SEQ.ID.NO.:489 T372K Dopamine D3 SEQ.ID.NO.:490 SEQ.ID.NO.:491 T328K Dopamine D5 SEQ.ID.NO.:492 SEQ.ID.NO.:493 L295K ETA SEQ.ID.NO.:494 SEQ.ID.NO.:495 A305K ETB SEQ.ID.NO.:496 SEQ.ID.NO.:497 A322K FPR1 SEQ.ID.NO.:498 SEQ.ID.NO.:499 L240K FPRL1 SEQ.ID.NO.:500 SEQ.ID.NO.:501 L240K GALR1 SEQ.ID.NO.:502 SEQ.ID.NO.:503 A246K GALR2 SEQ.ID.NO.:504 SEQ.ID.NO.:505 T235K GIP SEQ.ID.NO.:506 SEQ.ID.NO.:507 T343P mGluR1 SEQ.ID.NO.:346 SEQ.ID.NO.:347 3′ Deletion GPR5 SEQ.ID.NO.:508 SEQ.ID.NO.:509 V224K GPR24 (also known as MCH or SLC-1) T255K SEQ.ID.NO.:350 SEQ.ID.NO.:351 T255K/T257R SEQ.ID.NO.:354 SEQ.ID.NO.:355 24-IC3-SST2 SEQ.ID.NO.:358 SEQ.ID.NO.:359 C305Y SEQ.ID.NO.:362 SEQ.ID.NO.:363 P271L SEQ.ID.NO.:366 SEQ.ID.NO.:367 W269C SEQ.ID.NO.:370 SEQ.ID.NO.:371 W269F SEQ.ID.NO.:374 SEQ.ID.NO.:375 W269L SEQ.ID.NO.:378 SEQ.ID.NO.:379 F265I SEQ.ID.NO.:382 SEQ.ID.NO.:383 I261Q SEQ.ID.NO.:386 SEQ.ID.NO.:387 D140N SEQ.ID.NO.:390 SEQ.ID.NO.:391 GRPR SEQ.ID.NO.:510 SEQ.ID.NO.:511 A263K M1 SEQ.ID.NO.:512 SEQ.ID.NO.:513 A364K M2 SEQ.ID.NO.:514 SEQ.ID.NO.:515 T386K M3 SEQ.ID.NO.:516 SEQ.ID.NO.:517 A490K M4 SEQ.ID.NO.:518 SEQ.ID.NO.:519 T399K M5 SEQ.ID.NO.:520 SEQ.ID.NO:521 A441K MC3 SEQ.ID.NO.:522 SEQ.ID.NO.:523 A241K NK1R SEQ.ID.NO.:524 SEQ.ID.NO.:525 V247K NK2R SEQ.ID.NO.:526 SEQ.ID.NO.:527 V249K NK3R SEQ.ID.NO.:528 SEQ.ID.NO.:529 V298K NMBR SEQ.ID.NO.:530 SEQ.ID.NO.:531 A265K NPY5 SEQ.ID.NO.:532 SEQ.ID.NO.:533 A297K NTSR1 SEQ.ID.NO.:534 SEQ.ID.NO.:535 V302K NTSR2 SEQ.ID.NO.:536 SEQ.ID.NO.:537 V269K OPRD SEQ.ID.NO.:538 SEQ.ID.NO.:539 T260K OPRL1 SEQ.ID.NO.:540 SEQ.ID.NO.:541 T262K OPRK SEQ.ID.NO.:542 SEQ.ID.NO.:543 T273K OPRM SEQ.ID.NO.:544 SEQ.ID.NO.:545 T281K OPRM1A SEQ.ID.NO.:546 SEQ.ID.NO.:547 T281K OX₁R SEQ.ID.NO.:548 SEQ.ID.NO.:549 F367K OX₂R SEQ.ID.NO.:550 SEQ.ID.NO.:551 A297K PACAP SEQ.ID.NO.:552 SEQ.ID.NO.:553 T355K PAF SEQ.ID.NO.:554 SEQ.ID.NO.:555 L231K POE EP1 SEQ.ID.NO.:556 SEQ.ID.NO.:557 V296K PGE EP2 SEQ.ID.NO.:558 SEQ.ID.NO.:559 L263K POE EP4 SEQ.ID.NO.:560 SEQ.ID.NO.:561 V271K PTIR1 SEQ.ID.NO.:562 SEQ.ID.NO.:563 T410P PTHR2 SEQ.ID.NO.:564 SEQ.ID.NO.:565 T365P SCTR SEQ ID.NO.:566 SEQ.ID.NO.:567 T344P SST1 SEQ.ID.NO.:568 SEQ.ID.NO.:569 T290K SST2 SEQ.ID.NO.:570 SEQ.ID.NO.:571 T255K SST3 SEQ.ID.NO.:572 SEQ.ID.NO.:573 T256K SST4 SEQ.ID.NO.:574 SEQ.ID.NO.:575 T258K SST5 SEQ.ID.NO.:576 SEQ.ID.NO.:577 T247K TSHR V509A SEQ.ID.NO.:394 SEQ.ID.NO.:395 D619G SEQ.ID.NO.:398 SEQ.ID.NO.:399 A6231 SEQ.ID.NO.:402 SEQ.ID.NO.:403 A623K SEQ.ID.NO.:406 SEQ.ID.NO.:407 C672Y SEQ.ID.NO.:410 SEQ.ID.NO.:411 D619G/A623K SEQ.ID.NO.:414 SEQ.ID.NO.:415 V509A/C672Y SEQ.ID.NO.:418 SEQ.ID.NO.:419 V509A/A623K1C672Y SEQ.ID.NO.:422 SEQ ID.NO.:423 VIPR SEQ.ID.NO.:578 SEQ.ID.NO.:579 T343P VIPR2 SEQ.ID.NO.:580 SEQ.ID.NO.:581 T330P

[0223] Assessment of constitutive activity of the non-endogenous versions of the known GPCRs can then be accomplished.

Example 3

[0224] Receptor Expression

[0225] Although a variety of cells are available to the art for the expression of proteins, it is most preferred that mammalian cells be utilized. The primary reason for this is predicated upon practicalities, i.e., utilization of, e.g., yeast cells for the expression of a GPCR, while possible, introduces into the protocol a non-mammalian cell which may not (indeed, in the case of yeast, does not) include the receptor-coupling, genetic-mechanism and secretary pathways that have evolved for mammalian systems—thus, results obtained in non-mammalian cells, while of potential use, are not as preferred as that obtained from mammalian cells. Of the mammalian cells, COS-7, Hek-293 and Hek-293T cells are particularly preferred, although the specific mammalian cell utilized can be predicated upon the particular needs of the artisan. The following approach was used for the indicated receptors, and can also be applied with respect to other receptors disclosed herein.

[0226] On day one, 2×10⁴ Hek-293T cells well were plated out. On day two, two reaction tubes were prepared (the proportions to follow for each tube are per plate): tube A was prepared by mixing 20 μg DNA (e.g., pCMV vector; pCMV vector with receptor cDNA, etc.) in 1.2 ml serum free DMEM (Irvine Scientific, Irvine, Calif.); tube B was prepared by mixing 120 μl lipofectamine (Gibco BRL) in 1.2 ml serum free DMEM. Tubes A and B were admixed by inversions (several times), followed by incubation at room temperature for 30-45 min. The admixture is referred to as the “transfection mixture”. Plated Hek-293T cells were washed with 1×PBS, followed by addition of 10 ml serum free DMEM. 2.4 ml of the transfection mixture were added to the cells, followed by incubation for 4 hrs at 37° C./5% CO₂. The transfection mixture was removed by aspiration, followed by the addition of 25 ml of DMEM/10% Fetal Bovine Serum. Cells were incubated at 37° C./5% CO₂. After 72 hr incubation, cells were harvested and utilized for analysis.

Example 4

[0227] Assays for Determination of Constitutive Activity of Non-Endogenous GPCRS

[0228] A variety of approaches are available for assessment of constitutive activity of the non-endogenous versions of known GPCRs. The following are illustrative; those of ordinary skill in the art are credited with the ability to determine those techniques that are preferentially beneficial for the needs of the artisan.

[0229] 1. Membrane Binding Assays: [³⁵S]GTPγS Assay

[0230] When a G protein-coupled receptor is in its active state, either as a result of ligand binding or constitutive activation, the receptor couples to a G protein and stimulates the release of GDP and subsequent binding of GTP to the G protein. The alpha subunit of the G protein-receptor complex acts as a GTPase and slowly hydrolyzes the GTP to GDP, at which point the receptor normally is deactivated. Constitutively activated receptors continue to exchange GDP for GTP. The non-hydrolyzable GTP analog, [³⁵5]GTPγS, can be utilized to demonstrate enhanced binding of [³⁵S]GTPγS to membranes expressing constitutively activated receptors. The advantage of using [³⁵S]GTPγS binding to measure constitutive activation is that: (a) it is generically applicable to all G protein-coupled receptors; (b) it is proximal at the membrane surface making it less likely to pick-up molecules which affect the intracellular cascade.

[0231] The assay utilizes the ability of G protein coupled receptors to stimulate [³⁵S]GTPγS binding to membranes expressing the relevant receptors. The assay can, therefore, be used in the direct identification method to screen candidate compounds to known, and constitutively activated G protein-coupled receptors. The assay is generic and has application to drug discovery at all G protein-coupled receptors.

[0232] The [³⁵S]GTPγS assay can be incubated in 20 mM HEPES and between 1 and about 20 mM MgCl₂ (this amount can be adjusted for optimization of results, although 20 mM is preferred) pH 7.4, binding buffer with between about 0.3 and about 1.2 nM [³⁵S]GTPγS (this amount can be adjusted for optimization of results, although 1.2 is preferred) and 12.5 to 75 μg membrane protein (e.g, COS-7 cells expressing the receptor; this amount can be adjusted for optimization, although 75 μg is preferred) and 1 μM GDP (this amount can be changed for optimization) for 1 hour. Wheatgerm agglutinin beads (25 μl; Amersham) should then be added and the mixture incubated for another 30 minutes at room temperature. The tubes are then centrifuged at 1500×g for 5 minutes at room temperature and then counted in a scintillation counter.

[0233] A less costly but equally applicable alternative has been identified which also meets the needs of large scale screening. Flash plates™ and Wallac™ scintistrips may be utilized to format a high throughput [³⁵S]GTPγS binding assay. Furthermore, using this technique, the assay can be utilized for known GPCRs to simultaneously monitor tritiated ligand binding to the receptor at the same time as monitoring the efficacy via [³⁵S]GTPγS binding. This is possible because the Wallac beta counter can switch energy windows to look at both tritium and ³⁵S-labeled probes. This assay may also be used to detect other types of membrane activation events resulting in receptor activation. For example, the assay may be used to monitor ³²P phosphorylation of a variety of receptors (both G protein coupled and tyrosine kinase receptors). When the membranes are centrifuged to the bottom of the well, the bound [³⁵S]GTPγS or the ³²P-phosphorylated receptor will activate the scintillant which is coated of the wells. Scinti® strips (Wallac) have been used to demonstrate this principle. In addition, the assay also has utility for measuring ligand binding to receptors using radioactively labeled ligands. In a similar manner, when the radiolabeled bound ligand is centrifuged to the bottom of the well, the scintistrip label comes into proximity with the radiolabeled ligand resulting in activation and detection.

[0234] 2. Membrane-Based cAMP

[0235] A Flash Plate™ Adenylyl Cyclase kit (New England Nuclear; Cat. No. SMP004A) designed for cell-based assays can be modified for use with crude plasma membranes. The Flash Plate wells contain a scintillant coating which also contains a specific antibody recognizing cAMP. The cAMP generated in the wells was quantitated by a direct competition for binding of radioactive cAMP tracer to the cAMP antibody. The following serves as a brief protocol for the measurement of changes in cAMP levels in membranes that express the receptors.

[0236] Transfected cells are harvested approximately three days after transfection. Membranes were prepared by homogenization of suspended cells in buffer containing 20 mM HEPES, pH 7.4 and 10 mM MgCl₂. Homogenization is performed on ice using a Brinkman Polytron™ for approximately 10 seconds. The resulting homogenate is centrifuged at 49,000×g for 15 minutes at 4° C. The resulting pellet is then resuspended in buffer containing 20 mM HEPES, pH 7.4 and 0.1 mM EDTA, homogenized for 10 seconds, followed by centrifugation at 49,000×g for 15 minutes at 4° C. The resulting pellet can be stored at −80° C. until utilized. On the day of measurement, the membrane pellet is slowly thawed at room temperature, resuspended in buffer containing 20 mM HEPES, pH 7.4 and 10 mM MgCl₂ (these amounts can be optimized, although the values listed herein are preferred), to yield a final protein concentration of 0.60 mg/ml (the resuspended membranes were placed on ice until use).

[0237] cAMP standards and Detection Buffer (comprising 2 μCi of tracer [¹²⁵I cAMP (100 μl)] to 11 ml Detection Buffer) are prepared and maintained in accordance with the manufacturer's instructions. Assay Buffer is prepared fresh for screening and contained 20 mM HEPES, pH 7.4, 10 mM MgCl₂, 20 mM (Sigma), 0.1 units/ml creatine phosphokinase (Sigma), 50 μM GTP (Sigma), and 0.2 mM ATP (Sigma); Assay Buffer can be stored on ice until utilized. The assay is initiated by the addition of 50 μL of assay buffer followed by addition of 50 μL of membrane suspension to the NEN Flash Plate. The resultant assay mixture is incubated for 60 minutes at room temperature followed by addition of 100 μL of detection buffer. Plates are then incubated an additional 24 hours followed by counting in a Wallac MicroBeta™ scintillation counter. Values of cAMP/well are extrapolated from a standard cAMP curve that is contained within each assay plate.

[0238] 3. Cell-Based cAMP for Gi Coupled Target GPCRs

[0239] TSHR is a Gs coupled GPCR that causes the accumulation of cAMP upon activation. TSHR was constitutively activated by mutating amino acid residue 623 (i.e., changing an alanine residue to an isoleucine residue). See, SEQ.ID.NO.:402 for nucleic acid sequence and SEQ.ID.NO.:403 for deduced amino acid sequence. A Gi coupled receptor is expected to inhibit adenylyl cyclase, and, therefore, decrease the level of cAMP production, which can make assessment of cAMP levels challenging. An effective technique for measuring the decrease in production of cAMP as an indication of constitutive activation of a Gi coupled receptor can be accomplished by co-transfecting, most preferably, non-endogenous, constitutively activated TSHR (TSHR-A623I) (or an endogenous, constitutively active Gs coupled receptor) as a “signal enhancer” with a Gi linked target GPCR, such as GPR24, to establish a baseline level of cAMP. Upon creating a non-endogenous version of the Gi coupled receptor, this non-endogenous version of the target GPCR is then co-transfected with the signal enhancer, and it is this material that can be used for screening. We utilized such approach to effectively generate a signal when a cAMP assay is used; this approach is preferably used in the direct identification of candidate compounds against Gi coupled receptors. It is noted that for a Gi coupled GPCR, when this approach is used, an inverse agonist of the target GPCR will increase the cAMP signal and an agonist will decrease the cAMP signal.

[0240] On day one, 2×10⁴Hek-293 and Hek-293T cells/well were plated out. On day two, two reaction tubes were prepared (the proportions to follow for each tube are per plate): tube A was prepared by mixing 2 μg DNA of each receptor transfected into the mammalian cells, for a total of 4 μg DNA (e.g., pCMV vector; pCMV vector with mutated THSR (TSHR-A6231); TSHR-A623I and GPR24, etc.) in 1.2 ml serum free DMEM (Irvine Scientific, Irvine, Calif.); tube B was prepared by mixing 120 μl lipofectamine (Gibco BRL) in 1.2 ml serum free DMEM. Tubes A and B were then admixed by inversion (several times), followed by incubation at room temperature for 30-45 min. The admixture is referred to as the “transfection mixture”. Plated Hek-293 cells were washed with 1×PBS, followed by addition of 10 ml serum free DMEM. 2.4 ml of the transfection mixture was then added to the cells, followed by incubation for 4 hrs at 37° C./5% CO₂. The transfection mixture was then removed by aspiration, followed by the addition of 25 ml of DMEM/10% Fetal Bovine Serum. Cells were then incubated at 37° C./5% CO₂. After 24 hr incubation, cells were then harvested and utilized for analysis.

[0241] A Flash Plate™ Adenylyl Cyclase kit (New England Nuclear; Cat. No. SMP004A) designed for cell-based assays can be modified for use with crude plasma membranes. The Flash Plate wells can contain a scintillant coating which also contains a specific antibody recognizing cAMP. The cAMP generated in the wells can be quantitated by a direct competition for binding of radioactive cAMP tracer to the cAMP antibody. The following serves as a brief protocol for the measurement of changes in cAMP levels in whole cells that express the receptors.

[0242] Transfected cells were harvested approximately twenty four hours after transient transfection. Media was carefully aspirated and discarded. Ten milliliters of PBS was gently added to each dish of cells followed by careful aspiration. One milliliter of Sigma cell dissociation buffer and 3 ml of PBS are added to each plate. Cells were pipetted off the plate and the cell suspension is collected into a 50 ml conical centrifuge tube. Cells were then centrifuged at room temperature at 1,100 rpm for 5 min. The cell pellet was carefully re-suspended into an appropriate volume of PBS (about 3 ml/plate). The cells were then counted using a hemocytometer and additional PBS is added to give the appropriate number of cells (with a final concentration of about 50 μl/well).

[0243] cAMP standards and Detection Buffer (comprising 1 μCi of tracer [¹²⁵I cAMP (50 μl] to 11 ml Detection Buffer) was prepared and maintained in accordance with the manufacturer's instructions. Assay Buffer should be prepared fresh for screening and contained 50 μL of Stimulation Buffer, 3 μL of test compound (12 μM final assay concentration) and 50 μL cells, Assay Buffer can be stored on ice until utilized. The assay can be initiated by addition of 50 μL of cAMP standards to appropriate wells followed by addition of 50 μL of PBSA to wells H-11 and H12. Fifty μL of Stimulation Buffer was added to all wells. Selected compounds (e.g., TSH, 100 nM MCH, MCH/TSH) were added to appropriate wells using a pin tool capable of dispensing 3 μL of compound solution, with a final assay concentration of 12 μM test compound and 100 μL total assay volume. The cells were then added to the wells and incubated for 60 min at room temperature. 100 μL of Detection Mix containing tracer cAMP was then added to the wells. Plates were then incubated additional 2 hours followed by counting in a Wallac MicroBeta scintillation counter. Values of cAMP/well were then extrapolated from a standard cAMP curve which is contained within each assay plate.

[0244]FIG. 1 evidences about a 22% decrease in cAMP production of cells co-transfected with TSHR-A623I (in the presence of TSH) and non-endogenous, constitutively activated GPR24 (“24-IC3-SST2”) (262.266 pmol cAMP/well) compared to TSHR-A623I with endogenous GPR24 (“GPR24 wt”) (336.50293 pmol cAMP/well). Co-transfection of TSHR-A623I with non-endogenous, constitutively activated GPR24 (“I261Q”) evidences about a 27% decrease in production of cAMP when compared to “GPR24 wt.” Such a decrease in cAMP production signifies that non-endogenous version of GPR24 (“I261Q”) is constitutively active. Thus, a candidate compound which impacts the GPR24 receptor by increasing the cAMP signal is an inverse agonist, while a GPR24 agonist will decrease the cAMP signal. Based upon the data generated for FIG. 1, 24-IC3-SST2 and I261Q are most preferred non-endogenous versions of GPR24 when used in a TSHR (constitutively activated co-transfection approach using a cAMP assay.

[0245]FIG. 2 evidences about a 60% decrease in cAMP production of cells co-transfected with TSHR-A623I (in the presence of TSH) and non-endogenous, constitutively activated GPR5 (“V224K”) (23.5 pmole cAMP/well) compared to TSHR-A623I with endogenous GPR5 (“GPR5 wt”) (58.79 pmol cAMP/well). About a 78% and about a 45% decrease in production of cAMP was evidenced when comparing TSHR-A6231 co-transfected with “V225K” and TSHR-A623I co-transfected with “GPR5 wt” against pCMV co-transfected with TSHR-A623I (106.75 pmol cAMP/well), respectively. As mentioned above, a decrease in cAMP production evidences a constitutively active GPR5. Thus, a preferred candidate compound (i.e., an inverse agonist) would likely bind the Gi coupled receptor to increase the signal of activation.

[0246] Preferably, and as noted previously, to ensure that a small molecule candidate compound is targeting the Gi coupled target receptor and not, for example, the TSHR-A623I, the directly identified candidate compound is preferably screened against the signal enhancer in the absence of the target receptor.

[0247] C. Reporter-Based Assays

[0248] 1. CRE-Luc Reporter Assay (Gs-Associated Receptors)

[0249] A method to detect Gs stimulation depends on the known property of the transcription factor CREB, which is activated in a cAMP-dependent manner. A PathDetect™ CREB trans-Reporting System (Stratagene, Catalogue #219010) can utilized to assay for Gs coupled activity in 293 or 293T cells. Cells are transfected with the plasmids components of this above system and the indicated expression plasmid encoding endogenous or mutant receptor using a Mammalian Transfection Kit (Stratagene, Catalogue #200285) according to the manufacturer's instructions. Briefly, 400 ng pFR-Luc (luciferase reporter plasmid containing GaL4 recognition sequences), 40 ng pFA2-CREB (Ga14-CREB fusion protein containing the Ga14 DNA-binding domain), 80 ng pCMV-receptor expression plasmid (comprising the receptor) and 20 ng CMV-SEAP (secreted alkaline phosphatase expression plasmid; alkaline phosphatase activity is measured in the media of transfected cells to control for variations in transfection efficiency between samples) are combined in a calcium phosphate precipitate per the Kit's instructions. Half of the precipitate is equally distributed over 3 wells in a 96-well plate, kept on the cells overnight, and replaced with fresh medium the following morning. Forty-eight (48) hr after the start of the transfection, cells are treated and assayed for, e.g., luciferase activity

[0250] 2. 8XCRE-Luc Reporter Assay

[0251] HEK-293T cells are plated-out on 96 well plates at a density of 3×10⁴ cells per well and were transfected using Lipofectamine Reagent (BRL) the following day according to manufacturer instructions. A DNA/lipid mixture is prepared for each 6-well transfection as follows: 260 ng of plasmid DNA in 100 μl of DMEM were gently mixed with 2 μl of lipid in 100 μl of DMEM (the 260 ng of plasmid DNA consisted of 200 ng of a 8xCRE-Luc reporter plasmid (see below and FIG. 1 for a representation of a portion of the plasmid), 50 ng of pCMV comprising endogenous receptor or non-endogenous receptor or pCMV alone, and long of a GPRS expression plasmid (GPRS in pcDNA3 (Invitrogen)). The 8XCRE-Luc reporter plasmid was prepared as follows: vector SRIF-β-gal was obtained by cloning the rat somatostatin promoter (−71/+51) at BglV-HindIII site in the pβgal-Basic Vector (Clontech). Eight (8) copies of cAMP response element were obtained by PCR from an adenovirus template AdpCF126CCRE8 (see, 7 Human Gene Therapy 1883 (1996)) and cloned into the SRIF-β-gal vector at the Kpn-BglV site, resulting in the 8xCRE-β-gal reporter vector. The 8xCRE-Luc reporter plasmid was generated by replacing the beta-galactosidase gene in the 8xCRE-p-gal reporter vector with the luciferase gene obtained from the pGL3-basic vector (Promega) at the HindIII-BamHI site. Following 30 min. incubation at room temperature, the DNA/lipid mixture was diluted with 400 μl of DMEM and 100 μl of the diluted mixture was added to each well. 100 μl of DMEM with 10% FCS were added to each well after a 4 hr incubation in a cell culture incubator. The following day the transfected cells were changed with 200 μl/well of DMEM with 10% FCS. Eight (8) hours later, the wells were changed to 100 μl/well of DMEM without phenol red, after one wash with PBS. Luciferase activity were measured the next day using the LucLite™ reporter gene assay kit (Packard) following manufacturer instructions and read on a 1450 MicroBeta™ scintillation and luminescence counter (Wallac).

[0252]FIG. 3A represents about a 63% increase in activity of the non-endogenous, constitutively active version of human Dopamine D1 receptor (189270 relative light units) compared with that of the endogenous Dopamine D1 (70622 relative light units).

[0253]FIG. 3B represents about a 48% decreases in activity of the non-endogenous, constitutively active version of human OPRM (a Gi coupled receptor; see Example 4(3)), about a 53% decrease in activity of the non-endogenous, constitutively active version of human 5-HT1A (a Gi coupled receptor; see Example 4(3)), about a 91% increase in activity of the non-endogenous, constitutively active version of human 5-HT1B, and about a 20% increase in activity of the non-endogenous, constitutively active version of human 5-HT2B over the respective endogenous version of the GPCR.

[0254]FIG. 3C represents about a 29% increase in activity of the non-endogenous, constitutively active version of human CCR3, about a 41% increase in activity of the non-endogenous, constitutively active version of human NTSR1, about a 51% increase in activity of the non-endogenous, constitutively active version of human CB2, and about a 40% decrease in activity of the non-endogenous, constitutively active version of human CXCR4 (a Gi coupled receptor; see Example 4(3)) over the respective endogenous version of the GPCR.

[0255]FIG. 3D represents about a 75% increase in activity of the non-endogenous, constitutively active version of human PTHR1, about a 74% increase in activity of the non-endogenous, constitutively active version of human PTHR2, about a 56% increase in activity of the non-endogenous, constitutively active version of human SCTR, about a 96% increase in activity of the non-endogenous, constitutively active version of human PACAP, about a 88% increase in activity of the non-endogenous, constitutively active version of human VIPR1, and about a 91% increase in activity of the non-endogenous, constitutively active version of human VIPR2 over the respective endogenous version of the GPCR.

[0256]FIG. 3E represents about a 51% increase in activity of the non-endogenous, constitutively active version of human NTSR1, about a 31% decrease in activity of the non-endogenous, constitutively active version of human M1, about a 19% decrease in activity of the non-endogenous, constitutively active version of human M2, about a 32% increase in activity of the non-endogenous, constitutively active version of human M3, about a 33% decrease in activity of the non-endogenous, constitutively active version of human M4, about a 17% decrease in activity of the non-endogenous, constitutively active version of human M5, and about a 60% increase in activity of the non-endogenous, constitutively active version of human 5-HT1D over the respective endogenous version of the GPCR. M2, M4 and 5-HT1D are indicated as being Gi coupled while NTSR1, M1, M3 and M5 are indicated as being Gq coupled.

[0257] 3. AP1 Reporter Assay (Gq-Associated Receptors)

[0258] A method to detect Gq stimulation depends on the known property of Gq-dependent phospholipase C to cause the activation of genes containing AP1 elements in their promoter. A Pathdetect™ AP-1 cis-Reporting System (Stratagene, Catalog #219073) can be utilized following the protocol set forth above with respect to the CREB reporter assay, except that the components of the calcium phosphate precipitate were 410 ng pAP1-Luc, 80 ng pCMV-receptor expression plasmid, and 20 ng CMV-SEAP.

[0259] 4. SRF-Luc Reporter Assay (Gq-Associated Receptors)

[0260] One method to detect Gq stimulation depends on the known property of Gq-dependent phospholipase C to cause the activation of genes containing serum response factors in their promoter. A Pathdetect™ SRF-Luc-Reporting System (Stratagene) can be utilized to assay for Gq coupled activity in, e.g., COS7 cells. Cells are transfected with the plasmid components of the system and the indicated expression plasmid encoding endogenous or non-endogenous GPCR using a Mammalian Transfection™ Kit (Stratagene, Catalogue #200285) according to the manufacturer's instructions. Briefly, 410 ng SRF-Luc, 80 ng pCMV-receptor expression plasmid and 20 ng CMV-SEAP (secreted alkaline phosphatase expression plasmid; alkaline phosphatase activity is measured in the media of transfected cells to control for variations in transfection efficiency between samples) are combined in a calcium phosphate precipitate as per the manufacturer's instructions. Half of the precipitate is equally distributed over 3 wells in a 96-well plate, kept on the cells in a serum free media for 24 hours. The last 5 hours the cells are incubated with 1μM Angiotensin, where indicated. Cells are then lysed and assayed for luciferase activity using a Luclite™ Kit (Packard, Cat. #6016911) and “Trilux 1450 Microbeta” liquid scintillation and luminescence counter (Wallac) per the manufacturer's instructions. The data can be analyzed using GraphPad Prism™ 2.0a (GraphPad Software Inc.).

[0261] 5. Intracellular IP₃ Accumulation Assay (Gq-Associated Receptors)

[0262] On day 1, cells comprising the receptors (endogenous and/or non-endogenous) can be plated onto 24 well plates, usually 1×10⁵ cells/well (although this number can be optimized. On day 2 cells can be transfected by firstly mixing 0.25 μg DNA in 50 μL serum free DMEM/well and 2 μL lipofectamine in 50 μl serum-free DMEM/well. The solutions are gently mixed and incubated for 15-30 min at room temperature. Cells are washed with 0.5 ml PBS and 400 μl of serum free media is mixed with the transfection media and added to the cells. The cells are then incubated for 3-4 hrs at 37° C./5% CO₂ and then the transfection media is removed and replaced with 1 ml/well of regular growth media. On day 3 the cells are labeled with ³H-myo-inositol. Briefly, the media is removed and the cells are washed with 0.5 ml PBS. Then 0.5 ml inositol-free/serum free media (GIBCO BRL) is added/well with 0.25 μCi of ³H-myo-inositol/well and the cells are incubated for 16-18 hrs o/n at 37° C./5% CO₂. On Day 4 the cells are washed with 0.5 ml PBS and 0.45 ml of assay medium is added containing inositol-free/serum free media 10 μM pargyline 10 mM lithium chloride or 0.4 ml of assay medium and 50 μL of 10× ketanserin (ket) to final concentration of 10 μM. The cells are then incubated for 30 min at 37° C. The cells are then washed with 0.5 ml PBS and 200 μL of fresh/ice cold stop solution (1M KOH; 18 mM Na-borate; 3.8 mM EDTA) is added/well. The solution is kept on ice for 5-10 min or until cells were lysed and then neutralized by 200 μl of fresh/ice cold neutralization sol. (7.5% HCL). The lysate is then transferred into 1.5 ml eppendorf tubes and 1 ml of chloroform/methanol (1:2) is added/tube. The solution is vortexed for 15 sec and the upper phase is applied to a Biorad AG1-X8™ anion exchange resin (100-200 mesh). Firstly, the resin is washed with water at 1:1.25 W/V and 0.9 ml of upper phase is loaded onto the column. The column is washed with 10 mls of 5 mM myo-inositol and 10 ml of 5 mM Na-borate/60 mM Na-formate. The inositol tris phosphates are eluted into scintillation vials containing 10 ml of scintillation cocktail with 2 ml of 0.1 M formic acid/1 M ammonium formate. The columns are regenerated by washing with 10 ml of 0.1 M formic acid/3M ammonium formate and rinsed twice with H₂O and stored at 4° C. in water.

[0263]FIG. 4 represents two preferred non-endogenous, constitutively activated exemplary versions of GPR24, 24-IC3-SST2 and I261Q, for use in an IP3 assay. When compared to the endogenous version of GPR24 (“GPR24 wt”), 24-IC3-SST2 evidenced about a 27% increase in IP₃ accumulation, while the I26Q version represented and about a 32% increase.

Example 6

[0264] GPCR Fusion Protein Preparation

[0265] The design of the constitutively activated GPCR-G protein fusion construct was accomplished as follows: both the 5′ and 3′ ends of the rat G protein Gsoa (long form; Itoh, H. et al., 83 PNAS 3776 (1986)) were engineered to include a HindIII (5′-AAGCTT-3′) sequence thereon. Following confirmation of the correct sequence (including the flanking HindIII sequences), the entire sequence was shuttled into pcDNA3.1(−) (Invitrogen, cat. no. V795-20) by subcloning using the HindIII restriction site of that vector. The correct orientation for the Gsu. sequence was determined after subcloning into pcDNA3.1(−). The modified pcDNA3.1(−) containing the rat Gscc gene at HindIII sequence was then verified; this vector was now available as a “universal” Gscc protein vector. The pcDNA3.1 (−) vector contains a variety of well-known restriction sites upstream of the HindIII site, thus beneficially providing the ability to insert, upstream of the Gs protein, the coding sequence of an endogenous, constitutively active GPCR. This same approach can be utilized to create other “universal” G protein vectors, and, of course, other commercially available or proprietary vectors known to the artisan can be utilized—the important criteria is that the sequence for the GPCR be upstream and in-frame with that of the G protein.

[0266] 1. TSHR-Gsα Fusion Protein

[0267] a. Stable Cell Line Production for TSHR

[0268] Approximately 1.2 to 1.3×10⁷ HEK-293 cells are plated on a 15 cm tissue culture plate. Grown in DME High Glucose Medium containing ten percent fetal bovine serum and one percent sodium pyruvate, L-glutamine, and antibiotics. Twenty-four hours following plating of 293 cells to ˜80% confluency, the cells are transfected using 12 μg of DNA. The 12 μg of DNA is combined with 60 μL of lipofectamine and 2 mL of DME High Glucose Medium without serum. The medium is aspirated from the plates and the cells are washed once with medium without serum. The DNA, lipofectamine, and medium mixture is added to the plate along with 10 mL of medium without serum. Following incubation at 37° C. for four to five hours, the medium is aspirated and 25 ml of medium containing serum is added. Twenty-four hours following transfection, the medium is aspirated again, and fresh medium with serum is added. Forty-eight hours following transfection, the medium is aspirated and medium with serum is added containing geneticin (G418 drug) at a final concentration of 500 μg/mL. The transfected cells now undergo selection for positively transfected cells containing the G418 resistant gene. The medium is replaced every four to five days as selection occurs. During selection, cells are grown to create stable pools, or split for stable clonal selection.

[0269] b. TSHR(A623K) Fusion Protein

[0270] TSHR-Gsα Fusion Protein construct was then made as follows: primers were designed for both endogenous, constitutively activated and non-endogenous, constitutively activated TSAR were as follows: 5′-gatc[TCTAGA]ATGAGGCCGGCGGACTTGCTGC-3′ (SEQ.ID.NO.:582; sense) 5′-ctag[GATATC]CGCAAAACCGTTTGCATATACTC-3′. (SEQ.ID.NO.:583; antisense)

[0271] Nucleotides in lower caps are included as spacers just before the restriction sites between the endogenous TSHR and G protein. The sense and anti-sense primers included the restriction sites for XbaI and EcorV, respectively.

[0272] PCR was then utilized to secure the respective receptor sequences for fusion within the Gsα universal vector disclosed above, using the following protocol for each: 100 ng cDNA for TSHR(A623K) was added to separate tubes containing 2 μL of each primer (sense and anti-sense), 3 μL of 10 mM dNTPs, 10 μL of 10×TaqPlus™ Precision buffer, 1 μL of TaqPlus™ Precision polymerase (Stratagene: #600211), and 80 μL of water. Reaction temperatures and cycle times for TSHR were as follows: the initial denaturing step was done at 94° C. for five minutes, and a cycle of 94° C. for 30 seconds; 55° C. for 30 seconds; 72° C. for two minutes. A final extension time was done at 72° C. for ten minutes. PCR product for was run on a 1% agarose gel and then purified (data not shown). The purified product was digested with XbaI and EcorV (New England Biolabs) and the desired inserts isolated, purified and ligated into the Gs universal vector at the respective restriction site. The positive clones were isolated following transformation and determined by restriction enzyme digest; expression using Hek-293 cells was accomplished following the protocol set forth infra. Each positive clone for TSHR: Gs-Fusion Protein was sequenced and made available for the direct identification of candidate compounds. (See, SEQ.ID.NO.:588 for nucleic acid sequence and SEQ.ID.NO.:589 for amino acid sequence).

[0273] Location of non-endogenous version of TSHR(A623K) is located upstream from the rat G protein Gsox (i.e., from nucleotide 1 through 2,292; see, SEQ.ID.NO.:586 and amino acid residue 1 through 764; see, SEQ.ID.NO.:587). TSHR(A623K) can be linked directly to the G protein, or there can be spacer residues between the two. With respect to TSHR, 24 amino acid residues (an equivalent of 72 nucleotides) were placed in between the non-endogenous GPCR and the start codon for the G protein Gsu. Therefore, the Gs protein is located at nucleotide 2,365 through 3,549 (see, SEQ.ID.NO.:586) and at amino acid residue 789 through 1,183 (see, SEQ.ID.NO.:587). Those skilled in the art are credited with the ability to select techniques for constructing a GPCR Fusion Protein where the G protein is fused to the 3′ end of the GPCR of interest.

[0274] GPCR Fusion Protein was analyzed (to stabilize the GPCR while screening for candidate compounds, as shown in Example 6) and verified to be constitutively active utilizing the protocol found in Example 4(2). In FIG. 5, TSHR(A623K)-Gαs:Fusion Protein evidenced about an 87% increase in cAMP when compared to the control vector (pCMV).

[0275] 2. GPR24-Giα Fusion Protein

[0276] GPR24-Giα Fusion Protein construct was then made as follows: primers were designed for both endogenous, constitutively activated and non-endogenous, constitutively activated GPR24 were as follows: (SEQ.ID.NO.:584) 5′-GTGAAGCTTGCCCGGGCAGGATGGACCTGG-3′; sense (SEQ.ID.NO.:585) 5′-ATCTAGAGGTGCCTTTGCTTTCTG-3′; anitsense.

[0277] The sense and anti-sense primers included the restriction sites for KB4 and XbaI, respectively.

[0278] PCR was then utilized to secure the respective receptor sequences for fusion within the Gict universal vector disclosed above, using the following protocol for each: 100 ng cDNA for GPR24 was added to separate tubes containing 2 μL of each primer (sense and anti-sense), 3 μL of 10 mM dNTPs, 10 μL of 10×TaqPlus™ Precision buffer, 1 μL of TaqPlus™ Precision polymerase (Stratagene: #600211), and 80 μL of water. Reaction temperatures and cycle times for GPR24 were as follows: the initial denaturing step was done it 94° C. for five minutes, and a cycle of 94° C. for 30 seconds; 55° C. for 30 seconds; 72° C. for two minutes. A final extension time was done at 72° C. for ten minutes. PCR product for was run on a 1% agarose gel and then purified (data not shown). The purified product was digested with KB4 and XbaI (New England Biolabs) and the desired inserts will be isolated, purified and ligated into the Gi universal vector at the respective restriction site. The positive clones was isolated following transformation and determined by restriction enzyme digest; expression using Hek-293 cells was accomplished following the protocol set forth infra. Each positive clone for GPR24: Gi-Fusion Protein was sequenced and made available for the direct identification of candidate compounds. (See, SEQ.ID.NO.:590 for nucleic acid sequence and SEQ.ID.NO.:591 for amino acid sequence).

[0279] Endogenous version of GPR24 was fused upstream from the G protein Gi and is located at nucleotide 1 through 1,059 (see, SEE.ID.NO.:588) and amino acid residue 1 through 353 (see, SEQ.ID.NO.:589). With respect to GPR24, 2 amino acid residues (an equivalent of 6 nucleotides) were placed in between the endogenous (or non-endogenous) GPCR and the start codon for the G protein Giα. Therefore, the Gi protein is located at nucleotide 1,066 through 2,133 (see, SEQ.ID.NO.:588) and at amino acid residue 356 through 711 (see, SEQ.ID.NO.:589). Those skilled in the art are credited with the ability to select techniques for constructing a GPCR Fusion Protein where the G protein is fused to the 3′ end of the GPCR of interest.

[0280] Although it is indicated above that Gi coupled receptors, such as GPR24, can be used in conjunction with a co-transfection approach, this is in the context of cAMP based assays and is predicated upon the effect of Gi on cAMP levels. However, for other types of assays, such as a GTP based assay, the co-transfection approach is not essential. Thus for assays such as a GTP based assay, the GPCR Fusion Protein approach is preferred such that, with respect to a GTP based assay for GPR24, the GPR24:Gi Fusion Protein would be preferred.

Example 6

[0281] Protocol: Direct Identification of Inverse Agonists and Agonists Using [³⁵S]GTPγS

[0282] Although Endogenous GPCRs may be utilized for the direct identification of candidate compounds as, e.g., inverse agonists, for reasons that are not altogether understood, intra-assay variation can become exacerbated. Preferably, then, a GPCR Fusion Protein, as disclosed above, can also be utilized with a non-endogenous, constitutively activated GPCR. We can determine that when such a protein is used, intra-assay variation appears to be substantially stabilized, whereby an effective signal-to-noise ratio is obtained. This has the beneficial result of allowing for a more robust identification of candidate compounds. Thus, it is preferred that for direct identification, a GPCR Fusion Protein be used and that when utilized, the following assay protocols be utilized.

[0283] 1. Membrane Preparation

[0284] Membranes comprising the non-endogenous, constitutively active GPCR Fusion Protein of interest and for use in the direct identification of candidate compounds as inverse agonists, agonists or partial agonists are preferably prepared as follows:

[0285] a. Materials

[0286] “Membrane Scrape Buffer” is comprised of 20 mM HEPES and 10 mM EDTA, pH 7.4; “Membrane Wash Buffer” is comprised of 20 mM HEPES and 0.1 mM EDTA, pH 7.4; “Binding Buffer” is comprised of 20 mM HEPES, 100 mM NaCl, and 10 mM MgCl₂, pH 7.4.

[0287] b. Procedure

[0288] All materials will be kept on ice throughout the procedure. First, the media is aspirated from a confluent monolayer of cells, followed by rinse with 10 ml cold PBS, followed by a aspiration. Thereafter, 5 ml of Membrane Scrape Buffer will be added to scrape cells; this is followed by transfer of cellular extract into 50 ml centrifuge tubes (centrifuged at 20,000 rpm for 17 minutes at 4° C.). Thereafter, the supernatant is aspirated and the pellet is resuspended in 30 ml Membrane Wash Buffer followed by centrifugation at 20,000 rpm for 17 minutes at 4° C. The supernatant will then be aspirated and the pellet resuspended in Binding Buffer. This is then homogenized using a Brinkman Polytron™ homogenizer (15-20 second bursts until the all material is in suspension). This is referred to herein as “Membrane Protein”.

[0289] 2. Bradford Protein Assay

[0290] Following the homogenization, protein concentration of the membranes will be determined using the Bradford Protein Assay (protein can be diluted to about 1.5 mg/ml, aliquoted and frozen (−80° C.) for later use; when frozen, protocol for use is as follows: on the day of the assay, frozen Membrane Protein is thawed at room temperature, followed by vortex and then homogenized with a Polytron at about 12×1,000 rpm for about 5-10 seconds; it is noted that for multiple preparations, the homogenizer should be thoroughly cleaned between homogenization of different preparations).

[0291] a. Materials

[0292] Binding Buffer (as per above); Bradford Dye Reagent; Bradford Protein Standard are utilized, following manufacturer instructions (Biorad, cat. no. 500-0006).

[0293] b. Procedure

[0294] Duplicate tubes will be prepared, one including the membrane, and one as a control “blank”. Each contained 800 μL Binding Buffer. Thereafter, 10 μL of Bradford Protein Standard (1 mg/ml) is added to each tube, and 10 μL of membrane Protein is then added to just one tube (not the blank). Thereafter, 200 μL of Bradford Dye Reagent is added to each tube, followed by vortex of each. After five (5) minutes, the tubes will be re-vortexed and the material therein is transferred to cuvettes. The cuvettes are then read using a CECIL 3041 spectrophotometer, at wavelength 595.

[0295] 3. Direct Identification Assay

[0296] a. Materials

[0297] GDP Buffer consists of 37.5 ml Binding Buffer and 2 mg GDP (Sigma, cat. no. G-7127), followed by a series of dilutions in Binding Buffer to obtain 0.2 μM GDP (final concentration of GDP in each well was 0.1 μM GDP); each well comprising a candidate compound, will have a final volume of 200 μL consisting of 100 μL GDP Buffer (final concentration, 0.1 μM GDP), 50 μL Membrane Protein in Binding Buffer, and 50 μL [³⁵S]GTPγS (0.6 nM) in Binding Buffer (2.5 μL [³⁵S]GTPγS per 10 ml Binding Buffer).

[0298] b. Procedure

[0299] Candidate compounds are preferably screened using a 96-well plate format (these can be frozen at −80° C.). Membrane Protein (or membranes with expression vector excluding the GPCR Fusion Protein, as control) will be homogenized briefly until in suspension. Protein concentration is then determined using the Bradford Protein Assay set forth above. Membrane Protein (and control) is then diluted to 0.25 mg/ml in Binding Buffer (final assay concentration, 12.5 μg/well). Thereafter, 100 μL GDP Buffer will be added to each well of a Wallac Scintistrip™ (Wallac). A 5 μL pin-tool is then used to transfer 5 μL of a candidate compound into such well (i.e., 5 μL in total assay volume of 200 μL is a 1:40 ratio such that the final screening concentration of the candidate compound is 10 μM). Again, to avoid contamination, after each transfer step the pin tool should be rinsed in three reservoirs comprising water (1×), ethanol (1×) and water (2×)—excess liquid should be shaken from the tool after each rinse and dried with paper and kimwipes. Thereafter, 50 μL of Membrane Protein is added to each well (a control well comprising membranes without the GPCR Fusion Protein is also utilized), and pre-incubated for 5-10 minutes at room temperature. Thereafter, 50 μL of [³⁵S]GTPγS (0.6 nM) in Binding Buffer will be added to each well, followed by incubation on a shaker for 60 minutes at room temperature (again, in this example, plates were covered with foil). The assay is then stopped by spinning of the plates at 4000 RPM for 15 minutes at 22° C. The plates will then be aspirated with an 8 channel manifold and sealed with plate covers. The plates are then read on a Wallacc 1450 using setting “Prot. #37” (per manufacturer instructions).

Example 7

[0300] Protocol: Confirmation Assay

[0301] Using an independent assay approach to provide confirmation of a directly identified candidate compound as set forth above, it is preferred that a confirmation assay then be utilized. In this case, the preferred confirmation assay is a cyclase-based assay.

[0302] A modified Flash Plate™ Adenylyl Cyclase kit (New England Nuclear; Cat. No. SMP004A) is preferably utilized for confirmation of candidate compounds directly identified as inverse agonists and agonists to non-endogenous, constitutively activated GPCR in accordance with the following protocol.

[0303] Transfected cells will be harvested approximately three days after transfection. Membranes are prepared by homogenization of suspended cells in buffer containing 20 mM HEPES, pH 7.4 and 10 mM MgCl₂. Homogenization is performed on ice using a Brinkman Polytron™ for approximately 10 seconds. The resulting homogenate will be centrifuged at 49,000×g for 15 minutes at 4° C. The resulting pellet is then resuspended in buffer containing 20 mM IEPES, pH 7.4 and 0.1 mM EDTA, homogenized for 10 seconds, followed by centrifugation at 49,000×g for 15 minutes at 4° C. The resulting pellet can be stored at −80° C. until utilized. On the day of direct identification screening, the membrane pellet is slowly thawed at room temperature, resuspended in buffer containing 20 mM HEPES, pH 7.4 and 10 mM MgCl₂, to yield a final protein concentration of 0.60 mg/ml (the resuspended membranes are placed on ice until use).

[0304] cAMP standards and Detection Buffer (comprising 2 μCi of tracer [¹²⁵I cAMP (100 μl)] to 11 ml Detection Buffer) will be prepared and maintained in accordance with the manufacturer's instructions. Assay Buffer will be prepared fresh for screening and contained 20 mM HEPES, pH 7.4, 10 mM MgCl₂, 20 mM phospocreatine (Sigma), 0.1 units/ml creatine phosphokinase (Sigma), 50 μM GTP (Sigma), and 0.2 mM ATP (Sigma); Assay Buffer can be stored on ice until utilized.

[0305] Candidate compounds identified as per above (if frozen, thawed at room temperature) will then be added, preferably, to 96-well plate wells (3 μl/well; 12 μM final assay concentration), together with 40 μl Membrane Protein (30 μg/well) and 50 μl of Assay Buffer. This mixture is then incubated for 30 minutes at room temperature, with gentle shaking.

[0306] Following the incubation, 100 μl of Detection Buffer is added to each well, followed by incubation for 2-24 hours. Plates are then counted in a Wallac MicroBeta™ plate reader using “Prot. #31” (as per manufacturer instructions).

Example 8

[0307] Ligand-Based Confirmation Assay

[0308] Membranes will be prepared from transfected Hek-293 cells (see Example 3) by homogenization in 20 mM HEPES and 10 mM EDTA, pH 7.4 and centrifuged at 49,000×g for 15 min. The pellet will be resuspended in 20 mM HEPES and 0.1 mM EDTA, pH 7.4, homogenized for 10 sec using Polytron homogenizer (Brinkman) at 5000 rpm and centrifuged at 49,000×g for 15 min. The final pellet will be resuspended in 20 mM HEPES and 10 mM MgCl₂, pH 7.4, homogenized for 10 sec using Polytron homogenizer (Brinkman) at 5000 rpm.

[0309] Ligand-based confirmation assays will be performed in triplicate 200 μl volumes in 96 well plates. Assay buffer (20 mM HEPES and 10 mM MgCl₂, pH 7.4) will be used to dilute membranes, tritiated inverse agonists and/or agonists and the receptor's endogenous ligand (used to define non-specific binding). Final assay concentrations will consist of 1 nM of tritiated inverse agonist and/or agonist, 50 μg membrane protein (comprising the receptor) and 100 μm of endogenous ligand. Agonist assay will be incubated for 1 hr at 37° C., while inverse agonist assays are incubated for 1 hr at room temperature. Assays will terminate by rapid filtration onto Wallac Filtermat Type B with ice cold binding buffer using Skatron cell harvester. The radioactivity will be determined in a Wallac 1205 BetaPlate counter.

[0310] Again, this approach is used merely to understand the impact of the directly identified candidate compound on ligand binding. As those in the art will appreciate, it is possible that the directly identified candidate compounds may be allosteric modulators, (i.e., compounds that affect the functional activity of the receptor but which do not inhibit the endogenous ligand from binding to the receptor. Allosteric modulators include inverse agonists, partial agonists and agonists.

[0311] References cited throughout this patent document, including co-pending and related patent applications, unless otherwise indicated, are fully incorporated herein by reference. Modifications and extension of the disclosed inventions that are within the purview of the skilled artisan are encompassed within the above disclosure and the claims that follow.

[0312] Although a variety of expression vectors are available to those in the art, for purposes of utilization for both the endogenous and non-endogenous known GPCRs, it is most preferred that the vector utilized be pCMV. This vector was deposited with the American Type Culture Collection (ATCC) on Oct. 13, 1998 (10801 University Blvd., Manassas, Va. 20110-2209 USA) under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure. The DNA was tested by the ATCC and determined to be. The ATCC has assigned the following deposit number to pCMV: ATCC #203351.

0 SEQUENCE LISTING The patent application contains a lengthy “Sequence Listing” section. A copy of the “Sequence Listing” is available in electronic form from the USPTO web site (http://seqdata.uspto.gov/sequence.html?DocID=20030204073). An electronic copy of the “Sequence Listing” will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3). 

What is claimed is:
 1. A method for directly identifying a non-endogenous compound as a compound having an activity selected from the group consisting of: inverse agonists, parallel agonists, and partial agonists, to a non-endogenous, constitutively activated version of known G protein-coupled receptor, said receptor comprising a transmembrane-6 region and an intracellular region, comprising the steps of: (a) selecting a non-endogenous version of a known GPCR having an amino acid sequence selected from the group consisting of SEQ.ID.NO.:425; SEQ.ID.NO.:427; SEQ.ID.NO.:429; SEQ.ID.NO.:431; SEQ.ID.NO.:433; SEQ.ID.NO.:435; SEQ.ID.NO.:437; SEQ.ID.NO.:439; SEQ.ID.NO.:441; SEQ.ID.NO.:443; SEQ.ID.NO.:445; SEQ.ID.NO.:447; SEQ.ID.NO.:449; SEQ.ID.NO.:451; SEQ.ID.NO.:453; SEQ.ID.NO.:455; SEQ.ID.NO.:457; SEQ.ID.NO.:459; SEQ.ID.NO.:461; SEQ.ID.NO.:463; SEQ.ID.NO.:465; SEQ.ID.NO.:467; SEQ.ID.NO.:469; SEQ.ID.NO.:471; SEQ.ID.NO.:473; SEQ.ID.NO.:475; SEQ.ID.NO.:477; SEQ.ID.NO.:479; SEQ.ID.NO.:481; SEQ.ID.NO.:483; SEQ.ID.NO.:485; SEQ.ID.NO.:487; SEQ.ID.NO.:489; SEQ.ID.NO.:491; SEQ.ID.NO.:493; SEQ.ID.NO.:495; SEQ.ID.NO.:497; SEQ.ID.NO.:499; SEQ.ID.NO.:501; SEQ.ID.NO.:503; SEQ.ID.NO.:505; SEQ.ID.NO.:507; SEQ.ID.NO.:347; SEQ.ID.NO.:509; SEQ.ID.NO.:351; SEQ.ID.NO.:355; SEQ.ID.NO.:359; SEQ.ID.NO.:363; SEQ.ID.NO.:367; SEQ.ID.NO.:371; SEQ.ID.NO.:375; SEQ.ID.NO.:379; SEQ.ID.NO.:383; SEQ.ID.NO.:387; SEQ.ID.NO.:391; SEQ.ID.NO.:511; SEQ.ID.NO.:513; SEQ.ID.NO.:515; SEQ.ID.NO.:517; SEQ.ID.NO.:519; SEQ.ID.NO.:521; SEQ.ID.NO.:523; SEQ.ID.NO.:525; SEQ.ID.NO.:527; SEQ.ID.NO.:529; SEQ.ID.NO.:531; SEQ.ID.NO.:533; SEQ.ID.NO.:535; SEQ.ID.NO.:537; SEQ.ID.NO.:539; SEQ.ID.NO.:541; SEQ.ID.NO.:543; SEQ.ID.NO.:545; SEQ.ID.NO.:547; SEQ.ID.NO.:549: SEQ.ID.NO.:551; SEQ.ID.NO.:553; SEQ.ID.NO.:555; SEQ.ID.NO.:557; SEQ.ID.NO.:559; SEQ.ID.NO.:561: SEQ.ID.NO.:563: SEQ.ID.NO.:565; SEQ.ID.NO.:567; SEQ.ID.NO.:569; SEQ.ID.NO.:571; SEQ.ID.NO.:573; SEQ.ID.NO.:575; SEQ.ID.NO.:577; SEQ.ID.NO.:395; SEQ.ID.NO.:399; SEQ.ID.NO.:403; SEQ.ID.NO.:407; SEQ.ID.NO.:411; SEQ.ID.NO.:415; SEQ.ID.NO.:419; SEQ.ID.NO.:423; SEQ.ID.NO.:579; and SEQ.ID.NO.:581;

(b) confirming that the selected non-endogenous GPCR of step (a) is constitutively active; (c) contacting a non-endogenous candidate compound with the non-endogenous, constitutively activated GPCR of step of (b); and (d) determining, by measurement of the compound efficacy at said contacted receptor, whether said non-endogenous compound having inverse agonist activity as an inverse agonist or agonist activity is an agonist to said receptor of step (b).
 2. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:425.
 3. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:427
 4. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:429.
 5. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:431.
 6. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:433.
 7. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:435.
 8. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:437.
 9. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:439.
 10. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:441.
 11. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:443.
 12. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:445.
 13. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:447.
 14. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:449.
 15. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:451.
 16. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:453.
 17. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:455.
 18. The method of claim 1 wherein the non-endogenous GPCR of step (b)is an amino acid sequence having the sequence of SEQ.ID.NO.:457.
 19. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:459.
 20. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:461.
 21. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:463.
 22. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:465.
 23. The method of claim 1 wherein the non-endogenous GPCR of
 467. 24. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:469.
 25. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:471.
 26. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:473.
 27. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:475.
 28. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:477.
 29. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:479.
 30. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:481.
 31. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:483.
 32. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:485.
 33. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:487.
 34. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:489.
 35. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:491.
 36. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:493.
 37. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:495.
 38. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:497.
 39. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:499.
 40. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:501.
 41. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:503.
 42. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:505.
 43. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:507.
 44. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:347.
 45. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:509.
 46. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:351.
 47. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:355.
 48. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:359.
 49. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:361.
 50. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:367.
 51. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:371.
 52. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:375.
 53. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:379.
 54. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:383.
 55. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:387.
 56. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:391.
 57. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:511.
 58. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:513.
 59. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:515.
 60. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:517.
 61. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:519.
 62. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:521.
 63. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:523.
 64. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:525.
 65. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID).NO.:527.
 66. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:529.
 67. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:531.
 68. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:533.
 69. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:535.
 70. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:537.
 71. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:539.
 72. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:541.
 73. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:543.
 74. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:545.
 75. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:547.
 76. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:549.
 77. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:551.
 78. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:553.
 79. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:555.
 80. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:557.
 81. The method of claim 1 wherein the non-endogenous GPCR of step b is step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:559.
 82. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:561.
 83. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:563.
 84. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:565.
 85. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:567.
 86. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:569.
 87. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:571.
 88. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:573.
 89. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:575.
 90. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:577.
 91. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:395.
 92. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:399.
 93. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:403.
 94. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:407.
 95. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:411.
 96. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:415.
 97. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:419.
 98. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:423.
 99. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.ID.NO.:579.
 100. The method of claim 1 wherein the non-endogenous GPCR of step (b) is an amino acid sequence having the sequence of SEQ.I).NO.:581.
 101. The method of claim 1 further comprising the following step: assessing, by using an endogenous ligand based assay, the impact of the non-endogenous compound of step (d) on the binding of an endogenous ligand for the known GPCR version of the non-endogenous version of said known GPCR of step (a) with said known GPCR.
 102. The method of claim 101 wherein said non-endogenous compound is an allosteric modulator of said known GPCR. 